

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	4	MAY 10	CA/CAPLUS enhanced with 1900-1906 U.S. patent records
NEWS	5	MAY 11	KOREAPAT updates resume
NEWS	6	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS	7	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAPLUS and USPATFULL/USPAT2
NEWS	8	MAY 30	The F-Term thesaurus is now available in CA/CAPLUS
NEWS	9	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS	10	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS	11	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS	12	JUL 11	CHEMSAFE reloaded and enhanced
NEWS	13	JUL 14	FSTA enhanced with Japanese patents
NEWS	14	JUL 19	Coverage of Research Disclosure reinstated in DWPI
NEWS	15	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS	16	AUG 28	ADISCTI Reloaded and Enhanced
NEWS	17	AUG 30	CA(SM)/CAPLUS(SM) Austrian patent law changes
NEWS	18	SEP 11	CA/CAPLUS enhanced with more pre-1907 records
NEWS EXPRESS		JUNE 30	CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8
NEWS X25			X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 09:57:52 ON 15 SEP 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE  
ENTRY

TOTAL  
SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 09:58:09 ON 15 SEP 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 14 SEP 2006 HIGHEST RN 906714-10-1  
DICTIONARY FILE UPDATES: 14 SEP 2006 HIGHEST RN 906714-10-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006



Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10537851.str



chain nodes :  
10 11 12 13 15 18  
ring nodes :  
1 2 3 4 5 6 7  
chain bonds :  
1-10 11-13 11-12 13-15 15-18  
ring bonds :  
1-2 1-6 2-3 2-7 3-4 4-5 5-6 6-7  
exact/norm bonds :  
1-2 1-6 1-10 2-3 2-7 3-4 4-5 5-6 6-7 11-12 15-18  
exact bonds :  
11-13 13-15  
isolated ring systems :  
containing 1 :

G1:O,S,N



Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 10:CLASS 11:CLASS  
12:CLASS 13:CLASS 15:CLASS 18:Atom  
Generic attributes :  
18:  
Saturation : Unsaturated

L1        STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1        STR



G1 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 09:58:36 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED -        213 TO ITERATE

100.0% PROCESSED        213 ITERATIONS

10 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:    ONLINE    \*\*COMPLETE\*\*

                              BATCH    \*\*COMPLETE\*\*

PROJECTED ITERATIONS:        3385 TO        5135

PROJECTED ANSWERS:            11 TO        389

L2        10 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 09:58:40 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED -        4718 TO ITERATE

100.0% PROCESSED        4718 ITERATIONS

347 ANSWERS

SEARCH TIME: 00.00.01

L3        347 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

166.94

167.15

FILE 'CAPLUS' ENTERED AT 09:58:45 ON 15 SEP 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Sep 2006 VOL 145 ISS 12  
FILE LAST UPDATED: 13 Sep 2006 (20060913/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.  
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13 full

L4 18 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:631040 CAPLUS

DOCUMENT NUMBER: 145:103704

TITLE: Preparation of 3-(heterocyclylamino)pyrazole  
derivatives useful as anticancer agents

INVENTOR(S): Bhattacharya, Samit Kumar; Pan, Gonghua; Wishka, Donn  
Gregory

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 97 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006067614	A2	20060629	WO 2005-IB3933	20051214
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.:


US 2004-639175P

P 20041223

GI



I



II


AB The title compds. (I) and pharmaceutically acceptable salts and solvates thereof [W = N or (un)substituted CH and Z = N or CH, wherein at least one of W and Z = N; R1 = each (un)substituted 3 to 4 membered monocyclic or 5 to 7 membered bicyclic ring selected from heterocyclyl or carbocyclyl; R1 = (un)substituted 6 to 13 membered spiro-heterocyclyl ring; V = a bond, (un)substituted NH, O, S, (un)substituted CH2, (C1-C10)alkyl; X, Y = -T-R4 or L-Q-R4, or X and Y are taken together with their intervening atoms to form an (un)substituted fused 5 to 7 membered ring having 0 to 3 ring heteroatoms selected from O, S or N; T = a bond or (C1-C10)alkyl; wherein a methylene unit of said (C1-C10)alkyl group in V or T is optionally replaced by a unit consisting of O, S, NH, CO, CONH, NHCO, SO2, SO2NH, NHSO2, etc.; Q = (C1-C10)alkyl; L = O, S, SO2, NHSO2, SO2NH, NH, CO, CO2, or CHOC(O)-, etc. wherein NH or CH is optionally substituted; R2, R3 = -T-L-R6, -R7; or R2 and R3 are taken together with their intervening atoms to form an (un)substituted fused 5 to 9 membered ring; R4 = H, halo, cyano, R7, OR7, C(O)R7, CO2R7, each N-(un)substituted NH2, CONH2, SO2NH2, NHCOR7, -NHCOR7, or -NHC:SNH2, etc.; R6 = H, each (un)substituted C1-10 alkyl or C3-8 cycloalkyl; R7 = H, C1-10 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl-alkyl, C6-10 aryl-alkyl, 5 to 10 membered heteroaryl-alkyl, etc.] are prepared These compds. are Aurora kinase inhibitors which are able to modulate (reduce) the activity of the Aurora kinases in cancer cells (no data). The invention also relates to methods of treating abnormal cell growth in mammals by administering the compds. I and to pharmaceutical compns. for treating such disorders which contain the compds. I. Thus, 2-Chloro-N-(3-methyl-1H-pyrazol-5-yl)pyrido[2,3-d]pyrimidin-4-amine was condensed with (5-methyl-3-azabicyclo[3.1.0]hex-1-yl)carbamic acid tert-Bu ester in the presence of diisopropylethylamine in DMF at 90° for 1 h followed by treatment with CF3CO2H to give [2-(1-amino-5-methyl-3-azabicyclo[3.1.0]hex-3-yl)pyrido[2,3-d]pyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine trifluoroacetate which was condensed with cyclopropanesulfonyl chloride in the presence of Et3N in DMF at room temperature for 1 h to give cyclopropanesulfonic acid N-[5-methyl-3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]pyrido[2,3-d]pyrimidin-2-yl]-3-azabicyclo[3.1.0]hex-1-yl]amide (II).

IT 896463-41-5P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of 3-(heterocyclylamino)pyrazole derivs. useful as Aurora kinase inhibitors and anticancer agents)

RN 896463-41-5 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, N-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]thieno[3,2-d]pyrimidin-2-yl]-3-(phenylacetyl)-, (1R,5S)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L4 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:511214 CAPLUS

DOCUMENT NUMBER: 145:8186

TITLE: Preparation of pyrido[2,3-d]pyrimidines as anti-inflammatory agents

INVENTOR(S): Palle, Venkata P.; Singh, Rakesh Kumar; Malhotra, Sanjay; Waman, Yogesh Bhaskarrao; Verma, Ashwani; Ray, Abhijit; Sharma, Geeta

PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India

SOURCE: PCT Int. Appl., 105 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006056863	A1	20060601	WO 2005-IB3523	20051123
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.:

US 2004-630517P P 20041123

OTHER SOURCE(S): MARPAT 145:8186

GI



AB Title compds. I [R1 = alk(en/yn)yl, cycloalkyl, hetero/aryl, etc.; when X = O, S, R2 is defined as R1; when X =NH, N-acyl, N(CN), N(NO2), CH2 and derivs., CH(NO2), R2 = OH, alkoxy, aryloxy, CHO, CN, etc.; R3 = H,

alk(en/yn)yl, cycloalkyl, hetero/aryl, etc.; R4 = 3-azabicyclo[3.1.0]hex-6-yl, 3-oxa-7-azabicyclo[3.3.1]non-9-yl, 9-azabicyclo[3.3.1]non-3-yl, etc.; and pharmaceutically acceptable salts or solvates, esters, enantiomers, diastereomers, polymorphs, N-oxides, and metabolites thereof] were prepared as anti-inflammatory agents. For example, azabicyclo derivative II was


prepared

by reacting 6-(2-chlorophenyl)-8-methyl-2-methylsulfonyl-8H-pyrido[2,3-d]pyrimidin-7-one (preparation given) with (3-benzyl-3-azabicyclo[3.1.0]hex-6-yl)amine. The IC<sub>50</sub> values for TNF- $\alpha$  release from peripheral blood mononuclear cells for selected pyridopyrimidines I were found to range from about 2.3  $\mu$ M to about 12 nM. I showed p38 inhibitory activity in a range of from about 10  $\mu$ M to about 25 nM. Thus, I and their pharmaceutical compns. are useful for the prevention or treatment of inflammation and associated pathologies including inflammatory and autoimmune diseases such as sepsis, rheumatoid arthritis, inflammatory bowel disease, type-1 diabetes, asthma, chronic obstructive pulmonary disorder, organ transplant rejection and psoriasis.

IT 888493-38-7P, [4-[[[6-[[6-(2-Chlorophenyl)-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl]amino]-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]amino]phenyl]acetic acid methyl ester  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (drug candidate; preparation of pyrido[2,3-d]pyrimidines as anti-inflammatory agents)

RN 888493-38-7 CAPLUS


CN Benzeneacetic acid, 4-[[[6-[[6-(2-chlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



IT 888493-34-3P, [2-[(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)amino]-6-(2-chlorophenyl)-7-oxo-7H-pyrido[2,3-d]pyrimidin-8-yl]acetic acid ethyl ester 888493-35-4P, [2-[(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)amino]-6-(2-chlorophenyl)-7-oxo-7H-pyrido[2,3-d]pyrimidin-8-yl]acetic acid 888493-37-6P, 2-[2-[(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)amino]-6-(2-chlorophenyl)-7-oxo-7H-pyrido[2,3-d]pyrimidin-8-yl]acetamide 888493-39-8P, [4-[[[6-[[6-(2-Chlorophenyl)-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl]amino]-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]amino]phenyl]acetic acid  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of pyrido[2,3-d]pyrimidines as anti-inflammatory agents)


RN 888493-34-3 CAPLUS

CN Pyrido[2,3-d]pyrimidine-8(7H)-acetic acid, 6-(2-chlorophenyl)-7-oxo-2-[[3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 888493-35-4 CAPLUS

CN Pyrido[2,3-d]pyrimidine-8(7H)-acetic acid, 6-(2-chlorophenyl)-7-oxo-2-[[3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]amino]- (9CI) (CA INDEX NAME)




RN 888493-37-6 CAPLUS

CN Pyrido[2,3-d]pyrimidine-8(7H)-acetamide, 6-(2-chlorophenyl)-7-oxo-2-[[3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]amino]- (9CI) (CA INDEX NAME)



RN 888493-39-8 CAPLUS

CN Benzeneacetic acid, 4-[[[6-[[6-(2-chlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



ACCESSION NUMBER: 2006:494402 CAPLUS

DOCUMENT NUMBER: 145:8042

TITLE: Azabicyclic compounds as muscarinic receptor antagonists and their preparation, pharmaceutical compositions and use for treatment of disease of the respiratory, urinary and gastrointestinal systems

INVENTOR(S): Kumar, Naresh; Salman, Mohammad; Kaur, Kirandeep; Mehta, Anita; Arora, Sudershan K.; Chugh, Anita

PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India

SOURCE: PCT Int. Appl., 87 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006054162	A1	20060526	WO 2005-IB3459	20051118
WO 2006054162	C1	20060720		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: IN 2004-DE2331 A 20041119

OTHER SOURCE(S): CASREACT 145:8042; MARPAT 145:8042

GI



AB The invention generally relates to compds. of formula I as muscarinic receptor antagonists, which are useful for treating various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to processes for preparing compds. described herein, pharmaceutical compns. containing the disclosed compds., and the methods for treating diseases mediated through muscarinic receptors. Compds. of formula I wherein Ar is aryl, cycloalkyl, (hetero)aralkyl, or heterocyclyl(alkyl); X is alkyl, alkenyl, alkynyl, cycloalkyl, (hetero)aryl, (hetero)arylalkyl, or heterocyclylalkyl; R is H, OH, alkoxy, aryloxy, hydroxyalkyl, NH<sub>2</sub> and derivs., halo, alkyl, alkenyl, alkynyl, cycloalkyl, or aryl; Y is CO, CS, C(=Nacyl), C(=NNO<sub>2</sub>), C(=CHNO<sub>2</sub>), (un)substituted C=CH<sub>2</sub>, or CH<sub>2</sub>; T is (CH<sub>2</sub>)<sub>m</sub>, CQCH<sub>2</sub>, CHQ, or CH<sub>2</sub>OCH<sub>2</sub>; R<sup>1</sup> is

H, OH, alkoxy, hydroxyalkyl, aryloxy, CHO, CN, alkyl, alkenyl, alkynyl, cycloalkyl, carboxy, halo, (hetero)aryl(alkyl), acyl, heterocycl(alkyl), (CH<sub>2</sub>)<sub>k</sub>NH<sub>2</sub> and derivs., SO<sub>2</sub>R<sub>2</sub>, CO<sub>2</sub>R<sub>3</sub>, CONH<sub>2</sub> and derivs., NH<sub>2</sub> and derivs., OCONH<sub>2</sub> and derivs., or NHCHO and derivs.; n is an integer from 0-2; m is an integer from 0-3; k is an integer from 1-4; Q is alkyl, alkenyl, alkynyl, cycloalkyl, (hetero)aryl(alkyl), or heterocycl(alkyl); R<sub>2</sub> is alkyl, alkenyl, alkynyl, cycloalkyl, NH<sub>2</sub> and derivs., (hetero)aryl(alkyl), or (heterocycl)alkyl; R<sub>3</sub> is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl alkyl or heterocyclalkyl; and their pharmaceutically acceptable salts, solvates stereoisomers, and polymorphs and their process for preparation is claimed. Example compound II was prepared by hydrolysis of tert-butyl-benzyl-[3-[cyclopentyl(hydroxy)phenylacetyl]-3-azabicyclo[3.2.0]hex-6-yl]-carbamate. All the invention compds. were evaluated for their muscarinic receptor binding affinity. From the assay, it was determined that the example compds. exhibited pK<sub>i</sub> values for M<sub>2</sub> from about 5 to about 8.5, from about 5 to about 7.5, and from 5 to 7.1. For M<sub>3</sub>, the tested compds. exhibited pK<sub>i</sub> values from about 6 to 8.5, from about 6.7.7, and from about 5 to 6.9.


IT 888031-90-1P 888031-91-2P 888031-92-3P  
 888031-94-5P 888031-96-7P 888031-97-8P  
 888031-98-9P 888032-01-7P 888032-04-0P  
 888032-06-2P 888032-08-4P 888032-10-8P  
 888032-12-0P 888032-14-2P 888032-15-3P  
 888032-16-4P 888032-18-6P 888032-21-1P  
 888032-24-4P 888032-25-5P 888032-26-6P  
 888032-29-9P 888032-30-2P 888032-31-3P  
 888032-38-0P 888032-39-1P 888032-40-4P  
 888032-42-6P 888032-43-7P 888032-44-8P  
 888032-46-0P 888032-48-2P 888218-36-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of azabicyclic compds. as muscarinic receptor antagonists useful for treatment of disease of the respiratory, urinary and gastrointestinal systems)


RN 888031-90-1 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-(cyclopentylhydroxyphenylacetyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 888031-91-2 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-(cyclohexylhydroxyphenylacetyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 888031-92-3 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-[cyclopentylhydroxy(4-methylphenyl)acetyl]- (9CI) (CA INDEX NAME)




RN 888031-94-5 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane, 3-(cyclohexylhydroxyphenylacetyl)-6-(2-propenylamino)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 888031-93-4

CMF C22 H30 N2 O2




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.




RN 888031-96-7 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane, 3-[cyclohexylhydroxy(4-methylphenyl)acetyl]-6-(2-propenylamino)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 888031-95-6

CMF C23 H32 N2 O2




CM 2

CRN 87-69-4


CMF C4 H6 O6

Absolute stereochemistry.




RN 888031-97-8 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-[cyclopentylhydroxy(4-methylphenyl)acetyl]-N-2-propenyl- (9CI) (CA INDEX NAME)



RN 888031-98-9 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-(cyclopentylhydroxyphenylacetyl)-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 888032-01-7 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane, 3-[cyclopentyl(4-fluorophenyl)hydroxyacetyl]-6-(2-propenylamino)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 888032-00-6  
CMF C21 H27 F N2 O2



CM 2

CRN 87-69-4  
CMF C4 H6 O6


Absolute stereochemistry.



RN 888032-04-0 CAPLUS  
CN 3-Azabicyclo[3.1.0]hexane, 3-(2-hydroxy-3-methyl-1-oxo-2-phenylbutyl)-6-(2-propenylamino)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 888032-03-9  
CMF C19 H26 N2 O2



CM 2


CRN 87-69-4  
CMF C4 H6 O6

Absolute stereochemistry.




RN 888032-06-2 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-(cyclopentylhydroxyphenylacetyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 888032-08-4 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-(cyclobutylhydroxyphenylacetyl)-N-propyl- (9CI) (CA INDEX NAME)




RN 888032-10-8 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-[cyclohexylhydroxy(4-methylphenyl)acetyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 888032-12-0 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-[cyclohexyl(4-fluorophenyl)hydroxyacetyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 888032-14-2 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-[2-(4-fluorophenyl)-2-hydroxy-3-methyl-1-oxobutyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 888032-15-3 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-[cyclopentylhydroxy(4-methoxyphenyl)acetyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 888032-16-4 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-(cyclohexylhydroxyphenylacetyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 888032-18-6 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-(cyclopentylhydroxy-2-thienylacetyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 888032-21-1 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-[2-(4-fluorophenyl)-2-hydroxy-3-methyl-1-oxobutyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 888032-24-4 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-(cyclopentylhydroxyphenylacetyl)-  
(9CI) (CA INDEX NAME)




RN 888032-25-5 CAPLUS

CN Carbamic acid, [3-(cyclopentylhydroxyphenylacetyl)-3-azabicyclo[3.1.0]hex-  
6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 888032-26-6 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-(hydroxydiphenylacetyl)- (9CI) (CA  
INDEX NAME)



RN 888032-29-9 CAPLUS


CN Carbamic acid, [3-(cyclopentylhydroxyphenylacetyl)-3-azabicyclo[3.1.0]hex-  
6-yl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 888032-30-2 CAPLUS


CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-(cyclopentylhydroxyphenylacetyl)-N-  
methyl- (9CI) (CA INDEX NAME)






RN 888032-31-3 CAPLUS

CN Carbamic acid, [3-(hydroxydiphenylacetyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 888032-38-0 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-(cyclopentylhydroxy-2-thienylacetyl)- (9CI) (CA INDEX NAME)




RN 888032-39-1 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-(hydroxyphenyl-2-thienylacetyl)- (9CI) (CA INDEX NAME)




RN 888032-40-4 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-(cyclohexylhydroxyphenylacetyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 888032-42-6 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-(cyclopentylhydroxyphenylacetyl)-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 888032-43-7 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-(cyclohexylhydroxyphenylacetyl)-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 888032-44-8 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, N-methyl-3-(3,3,3-trifluoro-2-hydroxy-1-oxo-2-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 888032-46-0 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, N-methyl-3-[3,3,3-trifluoro-2-hydroxy-2-(4-methylphenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 888032-48-2 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane, 3-(cyclopentylhydroxyphenylacetyl)-6-(methylamino)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 888032-30-2


CMF C19 H26 N2 O2



CM 2

CRN 87-69-4  
CMF C4 H6 O6

Absolute stereochemistry.




RN 888218-36-8 CAPLUS  
CN 3-Azabicyclo[3.1.0]hexane, 3-(cyclopentylhydroxyphenylacetyl)-6-(methylamino)-, stereoisomer, stereoisomer of 2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 888218-35-7  
CMF C19 H26 N2 O2


Absolute stereochemistry.




CM 2

CRN 87-69-4  
CMF C4 H6 O6

Absolute stereochemistry.



IT 888032-54-0P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of azabicyclic compds. as muscarinic receptor antagonists useful for treatment of disease of the respiratory, urinary and gastrointestinal systems)  
RN 888032-54-0 CAPLUS  
CN Carbamic acid, [3-(cyclobutylhydroxyphenylacetyl)-3-azabicyclo[3.1.0]hex-6-yl]propyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:295302 CAPLUS

DOCUMENT NUMBER: 144:350723

TITLE: Preparation of phenyl-substituted amine diols and related compounds as muscarinic receptor antagonists for treating diseases such as those of the respiratory, urinary and gastrointestinal systems

INVENTOR(S): Salman, Mohammad; Sarma, Pakala Kumara Savithru; Dharmarajan, Sankaranarayanan; Chugh, Anita; Gupta, Suman

PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India

SOURCE: PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006032994	A2	20060330	WO 2005-IB2823	20050923
WO 2006032994	A3	20060504		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2004-613001P P 20040924

OTHER SOURCE(S): CASREACT 144:350723; MARPAT 144:350723


AB This present invention generally relates to muscarinic receptor antagonists (PhC(X)(OH)C(:G)CH<sub>2</sub>N(R<sub>1</sub>)(R<sub>2</sub>)(I) or PhC(X)(OH)C(G)CH<sub>2</sub>N(R<sub>1</sub>)(R<sub>2</sub>)(II); variables defined below; e.g. 1-cyclopentyl-3-([1,4]diazepan-1-yl)-1-hydroxy-1-phenylpropan-2-one), which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compds., pharmaceutical compns. containing the disclosed compds., and the methods for treating diseases mediated through muscarinic receptors. For I and II: X = alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, or heteroarylalkyl; R<sub>1</sub> = H, alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, aryloxy, -(CH<sub>2</sub>)<sub>0-2</sub>-heterocyclylalkyl, or -(CH<sub>2</sub>)<sub>0-2</sub>-heteroarylalkyl; R<sub>2</sub> = -(CH<sub>2</sub>)<sub>0-2</sub>-heteroaryl, -(CH<sub>2</sub>)<sub>0-2</sub>-heterocyclyl, or -(CH<sub>2</sub>)<sub>0-2</sub>-aryl, or R<sub>1</sub> and R<sub>2</sub> may together combine to form

a (un)saturated monocyclic or bicyclic ring system containing 0-4 heteroatoms (O, N or S) wherein the ring can be (un)substituted with  $\geq 1$  of alkyl, alkenyl, alkynyl, cycloalkyl, alkaryl, alkoxy, aryloxy, et al.; G = -OR [R = H or unsubstituted lower (C1-C6) alkyl], -NOR, -NHYR' (R' is H, alkyl or aryl and Y is -C(O), -SO or -SO<sub>2</sub>), or O (provided that R1 and R2 together does not form a pyrrolidine, 4-hydroxypiperidine, 4-pyrrolidinylpiperidine, piperazine or azabicyclo[3.1.0]hexane ring). Methods of preparation are claimed and preps. and/or characterization data for .apprx.80 examples of I are included. For example, 1-cyclopentyl-1-hydroxy-1-phenyl-3-(piperidin-1-yl)propan-2-one was prepared (86 %) from piperidine, Et<sub>3</sub>N and 3-bromo-1-cyclopentyl-1-hydroxy-1-phenyl-2-propanone (preparation described) in CH<sub>2</sub>Cl<sub>2</sub>. K<sub>i</sub> values for I tested in a radioligand binding assay range from .apprx.5 nM to .apprx.10  $\mu$ M for M<sub>2</sub> receptors, and from .apprx.0.5 nM to .apprx.10  $\mu$ M for M<sub>3</sub> receptors. Selectivity for bladder pressure inhibition vs. salivation was determined for compound 3 examples of I and was .apprx.2, similar to that determined for tolterodine.

IT 881098-10-8P, 3-[(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)(methyl)amino]-1-cyclopentyl-1-hydroxy-1-phenylpropan-2-one  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (drug candidate; preparation of Ph-substituted amine diols and related compds. as muscarinic receptor antagonists for treating diseases such as those of respiratory, urinary and gastrointestinal systems)

RN 881098-10-8 CAPLUS


CN 2-Propanone, 1-cyclopentyl-1-hydroxy-3-[methyl[3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]amino]-1-phenyl- (9CI) (CA INDEX NAME)



IT 881098-84-6P, 3-[(3-Azabicyclo[3.1.0]hex-6-yl)(methyl)amino]-1-cyclopentyl-1-hydroxy-1-phenylpropan-2-one  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of Ph-substituted amine diols and related compds. as muscarinic receptor antagonists for treating diseases such as those of respiratory, urinary and gastrointestinal systems)

RN 881098-84-6 CAPLUS

CN 2-Propanone, 3-(3-azabicyclo[3.1.0]hex-6-ylmethylamino)-1-cyclopentyl-1-hydroxy-1-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2006:194199 CAPLUS  
 DOCUMENT NUMBER: 144:274304  
 TITLE: Preparation of aminoheteroaryl compounds as c-Met tyrosine kinase inhibitors

INVENTOR(S): Cui, Jingrong Jean; Funk, Lee Andrew; Jia, Lei; Kung, Pei-Pei; Meng, Jerry Jialun; Nambu, Mitchell David; Pairish, Mason Alan; Shen, Hong; Tran-Dube, Michelle Bich

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: PCT Int. Appl., 171 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006021886	A1	20060302	WO 2005-IB2915	20050815
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006178374	A1	20060810	US 2005-213038	20050826
PRIORITY APPLN. INFO.:			US 2004-605279P	P 20040826
OTHER SOURCE(S):			MARPAT 144:274304	

GI



AB Aminoheteroaryl compds. (one Markush structure shown as I; variables defined below; e.g. 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[4-(isoxazol-5-yl)phenyl]pyridin-2-amine (shown as II)) are provided, as well

as methods for their synthesis and use. Preferred compds. are potent inhibitors of the c-Met protein kinase (K<sub>i</sub> values reported for 150 examples), and are useful in the treatment of abnormal cell growth disorders, such as cancers. For I: A = bond or C3-12 cycloalkyl, C6-12 aryl, 3-12 membered heteroalicyclic or 5-12 membered heteroaryl (each H in A optionally substituted); R<sub>2</sub> is H, halo, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C3-12 cycloalkyl, C6-12 aryl, 3-12 membered heteroalicyclic, 5-12 membered heteroaryl, -S(O)mR<sub>4</sub>, -SO<sub>2</sub>NR<sub>4</sub>R<sub>5</sub>, -S(O)OR<sub>4</sub>, -NO<sub>2</sub>, -NR<sub>4</sub>R<sub>5</sub>, -(CR<sub>6</sub>R<sub>7</sub>)nOR<sub>4</sub>, -CN, -C(O)R<sub>4</sub>, -OC(O)R<sub>4</sub>, -O(CR<sub>6</sub>R<sub>7</sub>)nR<sub>4</sub>, -NR<sub>4</sub>C(O)R<sub>5</sub>, -(CR<sub>6</sub>R<sub>7</sub>)nC(O)OR<sub>4</sub>, -(CR<sub>6</sub>R<sub>7</sub>)nNCR<sub>4</sub>R<sub>5</sub>, -C(:NR<sub>6</sub>)NR<sub>4</sub>R<sub>5</sub>, -NR<sub>4</sub>C(O)NR<sub>5</sub>R<sub>6</sub>, -NR<sub>4</sub>S(O)pR<sub>5</sub> or -C(O)NR<sub>4</sub>R<sub>5</sub>, and each H in R<sub>2</sub> is (un)substituted. R<sub>10</sub>, R<sub>11</sub> = independently H, halo, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C3-12 cycloalkyl, C6-12 aryl, 3-12 membered heteroalicyclic, 5-12 membered heteroaryl, -S(O)mR<sub>4</sub>, -SO<sub>2</sub>NR<sub>4</sub>R<sub>5</sub>, -S(O)OR<sub>4</sub>, -NO<sub>2</sub>, -NR<sub>4</sub>R<sub>5</sub>, -(CR<sub>6</sub>R<sub>7</sub>)nOR<sub>4</sub>, -CN, -C(O)R<sub>4</sub>, -OC(O)R<sub>4</sub>, -O(CR<sub>6</sub>R<sub>7</sub>)nR<sub>4</sub>, -NR<sub>4</sub>C(O)R<sub>5</sub>, -(CR<sub>6</sub>R<sub>7</sub>)nC(O)OR<sub>4</sub>, -(CR<sub>6</sub>R<sub>7</sub>)nOR<sub>4</sub>, -(CR<sub>6</sub>R<sub>7</sub>)nC(O)NR<sub>4</sub>R<sub>5</sub>, -(CR<sub>6</sub>R<sub>7</sub>)nNCR<sub>4</sub>R<sub>5</sub>, -C(:NR<sub>6</sub>)NR<sub>4</sub>R<sub>5</sub>, -NR<sub>4</sub>C(O)NR<sub>5</sub>R<sub>6</sub>, -NR<sub>4</sub>S(O)pR<sub>5</sub>, -C(O)NR<sub>4</sub>R<sub>5</sub>, -(CR<sub>6</sub>R<sub>7</sub>)n(3-12 membered heteroalicyclic), -(CR<sub>6</sub>R<sub>7</sub>)n(C3-12 cycloalkyl), -(CR<sub>6</sub>R<sub>7</sub>)n(C6-12 aryl), -(CR<sub>6</sub>R<sub>7</sub>)n(5-12 membered heteroaryl), or -(CR<sub>6</sub>R<sub>7</sub>)nC(O)NR<sub>4</sub>R<sub>5</sub> and each H in R<sub>10</sub> and R<sub>11</sub> is (un)substituted; addnl. details are given in the claims. Although the methods of preparation are not claimed, preps. and/or characterization data for .apprx.150 examples are included, but very few of them correspond to any Markush structure in the claims. For example, II was prepared from the 2,3-dimethylbutane-2,3-diyl substituted-pyridin-3-ylboronate and an aryl halide in DME in the presence of Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>.


IT 877620-74-1P, 1-(6-Amino-3-azabicyclo[3.1.0]hex-3-yl)-2-[4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]phenyl]ethanone

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of aminoheteroaryl compds. as c-Met tyrosine kinase inhibitors)

RN 877620-74-1 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-[[4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-3-pyridinyl]phenyl]acetyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1244913 CAPLUS

DOCUMENT NUMBER: 144:129206

TITLE: Cyclopropyl building blocks in organic synthesis. Part 116. An access to 3,4-(aminomethano)proline in racemic and enantiomerically pure form

AUTHOR(S): Brackmann, Farina; Schill, Heiko; de Meijere, Armin

CORPORATE SOURCE: Institut fuer Organische und Biomolekulare Chemie,  
Georg-August-Universitaet Goettingen, Goettingen,  
37077, Germany

SOURCE: Chemistry--A European Journal (2005), 11(22),  
6593-6600  
CODEN: CEUJED; ISSN: 0947-6539


PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA

DOCUMENT TYPE: Journal


LANGUAGE: English

OTHER SOURCE(S): CASREACT 144:129206

GI



I





II

- AB Protected racemic and enantiomerically pure 3,4-(aminomethano)prolines (2S\*,2'R\*,3R\*,4R\*)rac-I and (2S,2'R,3R,4R)-I have been prepared applying a titanium-mediated reductive cyclopropanation as a key step. Thus, cyclopropanations of N,N-dibenzylformamide with titanacyclopropanes generated in situ from racemic or enantiomerically pure tert-Bu N-Boc-3,4-dehydroprolinates (Boc = tert-butoxycarbonyl) (2S\*)rac-II or (2S)-II proceed diastereoselectively, and furnish the protected racemic and enantiomerically pure diamino acid I. The latter was incorporated into three tripeptides containing glycyl, alanyl and phenylalanyl moieties.
- IT 873544-19-5P 873544-23-1P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(stereoselective and asym. synthesis of racemic and enantiopure aminomethanoprolines and their incorporation into tripeptides)
- RN 873544-19-5 CAPLUS
- CN L-Phenylalanine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]glycyl-(1R,2S,5R,6R)-6-[[[(phenylmethoxy)carbonyl]amino]-3-azabicyclo[3.1.0]hexane-2-carbonyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).





RN 873544-23-1 CAPLUS  
 CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-(1R,2S,5R,6R)-6-  
 [[(phenylmethoxy)carbonyl]amino]-3-azabicyclo[3.1.0]hexane-2-carbonyl-,  
 methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).





REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2004:872782 CAPLUS  
 DOCUMENT NUMBER: 141:366130  
 TITLE: Preparation of substituted azabicyclo hexane derivatives as muscarinic receptor antagonists  
 INVENTOR(S): Mehta, Anita; Miriyala, Bruhaspathy; Arundutt, Silamkoti Viswanatham; Gupta, Jang Bahadur  
 PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India  
 SOURCE: PCT Int. Appl., 52 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004089899	A1	20041021	WO 2003-IB1327	20030410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003223010	A1	20041101	AU 2003-223010	20030410
EP 1615887	A1	20060118	EP 2003-718977	20030410
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			WO 2003-IB1327	A 20030410
OTHER SOURCE(S):			CASREACT 141:366130; MARPAT 141:366130	

GI



AB Title compds. I [] are prepared For instance, II is prepared from  
 (2S)-2-[3-oxocyclohexane-1-yl]-2-hydroxy-2-phenylacetic acid (preparation

given) and (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-6-amino-3-benzyl-3-azabicyclo[3.1.0]hexane (prior art). Selected examples exhibit affinity for the muscarinic M2 and M3 receptors. I are useful in the treatment of urinary incontinence.

IT 776299-83-3P 776299-84-4P 776299-85-5P  
 776299-86-6P 776299-87-7P 776299-88-8P  
 776299-89-9P 776299-90-2P 776299-91-3P  
 776299-92-4P 776299-93-5P 776299-97-9P  
 776299-98-0P 777860-44-3P 777860-45-4P  
 777860-46-5P 777860-47-6P 777860-48-7P  
 777860-49-8P 777860-50-1P 777860-51-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted azabicyclo hexane derivs. as muscarinic M2 and M3 receptor antagonists)

RN 776299-83-3 CAPLUS

CN Benzeneacetamide,  $\alpha$ -hydroxy- $\alpha$ -(3-oxocyclohexyl)-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 776299-84-4 CAPLUS

CN Benzeneacetamide,  $\alpha$ -(3-fluorocyclohexyl)- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 776299-85-5 CAPLUS


CN Benzeneacetamide,  $\alpha$ -(3-fluorocyclopentyl)- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 776299-86-6 CAPLUS  
 CN Benzeneacetamide,  $\alpha$ -[(1R)-3,3-difluorocyclohexyl]- $\alpha$ -hydroxy-N-  
 [(1R,5S)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]-, ( $\alpha$ S)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 776299-87-7 CAPLUS  
 CN Benzeneacetamide,  $\alpha$ -[(1R)-3,3-difluorocyclopentyl]- $\alpha$ -hydroxy-N-  
 [(1R,5S)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]-, ( $\alpha$ S)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 776299-88-8 CAPLUS  
 CN Benzeneacetamide, N-[(1R,5S)-3-[2-(1,3-benzodioxol-5-yl)ethyl]-3-  
 azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -(3,3-difluorocyclohexyl)- $\alpha$ -  
 hydroxy-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 776299-89-9 CAPLUS  
 CN Benzeneacetamide, N-[(1R,5S)-3-[2-(1,3-benzodioxol-5-yl)ethyl]-3-  
 azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -(1R)-3,3-difluorocyclopentyl]- $\alpha$ -  
 hydroxy-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 776299-90-2 CAPLUS

CN Benzeneacetamide, N-[(1R,5S)-3-[2-(1,3-benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]-α-(3-fluorocyclohexyl)-α-hydroxy-, (αS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 776299-91-3 CAPLUS

CN Benzeneacetamide, N-[(1R,5S)-3-[2-(1,3-benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]-α-(3-fluorocyclopentyl)-α-hydroxy-, (αS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 776299-92-4 CAPLUS

CN Benzeneacetamide, α-[(1R)-3,3-difluorocyclohexyl]-α-hydroxy-N-[(1R,5S)-3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hex-6-yl]-, (αS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 776299-93-5 CAPLUS

CN Benzeneacetamide, α-[(1R)-3,3-difluorocyclopentyl]-α-hydroxy-N-

[(1R,5S)-3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hex-6-yl]-,  
( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 776299-97-9 CAPLUS

CN Benzeneacetamide,  $\alpha$ -(3-fluorocyclohexyl)- $\alpha$ -hydroxy-N-  
[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(4-methyl-3-pentenyl)-3-  
azabicyclo[3.1.0]hex-6-yl]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 776299-98-0 CAPLUS

CN Benzeneacetamide,  $\alpha$ -(3-fluorocyclopentyl)- $\alpha$ -hydroxy-N-  
[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(4-methyl-3-pentenyl)-3-  
azabicyclo[3.1.0]hex-6-yl]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 777860-44-3 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[(1S)-3,3-difluorocyclohexyl]- $\alpha$ -hydroxy-N-  
[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-  
yl]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 777860-45-4 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[(1S)-3,3-difluorocyclopentyl]- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 777860-46-5 CAPLUS

CN Benzeneacetamide,  $\alpha$ -(3,3-difluorocyclopentyl)- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 777860-47-6 CAPLUS

CN Benzeneacetamide, N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[2-(1,3-benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -[(1S)-3,3-difluorocyclopentyl]- $\alpha$ -hydroxy-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 777860-48-7 CAPLUS

CN Benzeneacetamide, N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[2-(1,3-benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -(3,3-difluorocyclopentyl)- $\alpha$ -hydroxy-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 777860-49-8 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[(1S)-3,3-difluorocyclohexyl]- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hex-6-yl]-, ( $\alpha$ R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 777860-50-1 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[(1S)-3,3-difluorocyclopentyl]- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hex-6-yl]-, ( $\alpha$ S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 777860-51-2 CAPLUS

CN Benzeneacetamide,  $\alpha$ -(3,3-difluorocyclopentyl)- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hex-6-yl]-, ( $\alpha$ R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

2



THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



ACCESSION NUMBER: 2004:872781 CAPLUS  
 DOCUMENT NUMBER: 141:350045  
 TITLE: Preparation of substituted azabicyclo hexane derivatives as muscarinic receptor antagonists  
 INVENTOR(S): Mehta, Anita; Miriyala, Bruhaspathy; Arora, Sudershan Kumar; Gupta, Jang Bahadur  
 PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India  
 SOURCE: PCT Int. Appl., 36 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004089898	A1	20041021	WO 2003-IB1288	20030409
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003214520	A1	20041101	AU 2003-214520	20030409
EP 1618091	A1	20060125	EP 2003-710099	20030409
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			WO 2003-IB1288	A 20030409
OTHER SOURCE(S):			MARPAT 141:350045	

GI



AB Title compds. I [Ar = (hetero)aryl, etc.; R1 = H, alk(en/yn)yl, etc.; R2 = H, alkyl; A = (CH2)0-4, CO; W = (CH2)1-4; X = O, S, amino; Y = alkyl; R3-4 = H, alkyl, cycloalkyl, etc.] are prepared For instance, II is prepared from (3-benzyl-3-azabicyclo[3.1.0]hexan-6-yl)amine, 2-chloroacetyl chloride and (2-methoxy-5-methylphenyl)-3-phenylpropanoic acid. II exhibited pKi < 6 for both the muscarinic M2 and M3 receptors. I are useful for the treatment of respiratory, urinary and gastrointestinal disorders.


IT 777068-38-9P 777068-40-3P 777068-58-3P  
777068-64-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of substituted azabicyclo hexane derivs. as muscarinic M2 and M3 receptor antagonists)

RN 777068-38-9 CAPLUS

CN Benzenepropanoic acid, 2-methoxy-5-methyl-β-phenyl-,  
2-oxo-2-[[ (1α,5α,6α)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]amino]ethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 777068-40-3 CAPLUS

CN Benzenepropanoic acid, 5-methyl-β-phenyl-2-(phenylmethoxy)-,  
2-oxo-2-[[ (1α,5α,6α)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]amino]ethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 777068-58-3 CAPLUS

CN Benzenepropanamide, 2-hydroxy-5-methyl-β-phenyl-N-  
[(1α,5α,6α)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 777068-64-1 CAPLUS

CN Benzenepropanamide, 2-methoxy-5-methyl-β-phenyl-N-[(1α,5α,6α)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 777068-42-5P 777068-44-7P 777068-46-9P

777068-48-1P 777068-50-5P 777068-52-7P

777068-55-0P 777068-57-2P 777068-60-7P

777068-62-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted azabicyclo hexane derivs. as muscarinic M2 and M3 receptor antagonists)

RN 777068-42-5 CAPLUS

CN Benzenepropanamide, N-(1α,5α,6α)-3-azabicyclo[3.1.0]hex-6-yl-2-hydroxy-5-methyl-β-phenyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 777068-44-7 CAPLUS

CN Benzenepropanamide, N-(1α,5α,6α)-3-azabicyclo[3.1.0]hex-6-yl-2-methoxy-5-methyl-β-phenyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 777068-46-9 CAPLUS

CN Benzenepropanoic acid, 2-methoxy-5-methyl-β-phenyl-,  
4-[(1α,5α,6α)-3-azabicyclo[3.1.0]hex-6-yl[(1,1-  
dimethylethoxy)carbonyl]amino]butyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 777068-48-1 CAPLUS

CN Benzenepropanoic acid, 2-hydroxy-5-methyl-β-phenyl-,  
4-[(1α,5α,6α)-3-azabicyclo[3.1.0]hex-6-yl[(1,1-  
dimethylethoxy)carbonyl]amino]butyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 777068-50-5 CAPLUS

CN Benzenepropanoic acid, 2-methoxy-5-methyl-β-phenyl-,  
2-[(1α,5α,6α)-3-azabicyclo[3.1.0]hex-6-ylamino]-2-  
oxoethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 777068-52-7 CAPLUS

CN Benzenepropanoic acid, 2-hydroxy-5-methyl- $\beta$ -phenyl-,  
2-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-ylamino]-2-  
oxoethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 777068-55-0 CAPLUS

CN Benzenepropanamide, 2-hydroxy-5-methyl-N-[2-oxo-2-  
[[ (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-  
yl]amino]ethyl]- $\beta$ -phenyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 777068-57-2 CAPLUS

CN Benzenepropanamide, 2-methoxy-5-methyl-N-[2-oxo-2-  
[[ (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-  
yl]amino]ethyl]- $\beta$ -phenyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 777068-60-7 CAPLUS


CN Benzenepropanoic acid, 2-methoxy-5-methyl- $\beta$ -phenyl-,  
4-[[ (1,1-dimethylethoxy) carbonyl] [(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-  
(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]amino]butyl ester (9CI) (CA  
INDEX NAME)

Relative stereochemistry.



RN 777068-62-9 CAPLUS  
 CN Benzenepropanoic acid, 5-methyl-β-phenyl-2-(phenylmethoxy)-,  
 4-[[ (1,1-dimethylethoxy) carbonyl] [(1α,5α,6α)-3-  
 (phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]amino]butyl ester (9CI) (CA  
 INDEX NAME)

Relative stereochemistry.




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2004:675748 CAPLUS  
 DOCUMENT NUMBER: 141:207060  
 TITLE: Preparation of azabicyclo[3.1.0]hexanes as muscarinic  
 receptor antagonists  
 INVENTOR(S): Mehta, Anita; Miriyala, Bruhaspathy; Kumar, Naresh;  
 Gupta, Jang Bahadur  
 PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India  
 SOURCE: PCT Int. Appl., 37 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004069835	A1	20040819	WO 2003-IB416	20030207
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003205964	A1	20040830	AU 2003-205964	20030207
EP 1594871	A1	20051116	EP 2003-702847	20030207
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 PRIORITY APPLN. INFO.: WO 2003-IB416 A 20030207  
 OTHER SOURCE(S): CASREACT 141:207060; MARPAT 141:207060  
 GI



AB Title compds. [I; Ar = (substituted) aryl, heteroaryl; R1 = H, OH, HOCH2, aryl, alkylaryl, amino, alkoxy, carbamoyl, halo; R2 = alkyl, cycloalkyl, cycloalkenyl, (substituted) aryl, heteroaryl; W = (CH2)p; p = 0, 1; X = O, S, NR, null; Y = null, CHR5CO, Me, (CH2)q; q = 0-4; R5 = H; Z = null, NHR8CO; R8 = (CH2)r; r = 0-4; Q = (CH2)n; n = 0, 1; R6, R7 = H, Me, CO2H, CONH2, NH2, CH2NH2; R4 = H, (substituted) (unsatd.) hydrocarbyl], were prepared Thus, N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-azabicyclo[3.1.0]hexan-6-yl] 3,3,3-triphenylpropionamide, 4-methyl-3-pentenyl bromide, K2CO3, and KI were stirred in DMF at 60-70° for 3 h and at room temperature overnight to give N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(4-methyl-3-pentenyl)azabicyclo[3.1.0]hexan-6-yl] 3,3,3-triphenylpropionamide. I bound to M2 and M3 receptors with pKi <6.

IT 741676-03-9P 741676-04-0P 741676-05-1P  
 741676-06-2P 741676-08-4P 741676-09-5P  
 741676-10-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of azabicyclohexanes as muscarinic receptor antagonists)

RN 741676-03-9 CAPLUS

CN Benzenepropanamide,  $\beta,\beta$ -diphenyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 741676-04-0 CAPLUS

CN Benzenepropanamide, N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hex-6-yl]- $\beta,\beta$ -diphenyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 741676-05-1 CAPLUS

CN Benzenepropanamide, N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[2-(1,3-benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\beta$ , $\beta$ -diphenyl- (9CI)  
(CA INDEX NAME)


Relative stereochemistry.



RN 741676-06-2 CAPLUS

CN Benzenepropanamide, N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[2-(2,3-dihydro-5-benzofuranyl)-2-oxoethyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\beta$ , $\beta$ -diphenyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 741676-08-4 CAPLUS

CN  $\beta$ -Alaninamide, N-(1-oxo-3,3,3-triphenylpropyl)glycyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 741676-09-5 CAPLUS

CN Benzeneacetamide, N-(1 $\alpha$ ,5 $\alpha$ ,6 $\beta$ )-3-azabicyclo[3.1.0]hex-6-



yl-4-fluoro- $\alpha$ -(4-fluorophenyl)- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 741676-10-8 CAPLUS

CN Benzeneacetamide, N-(1 $\alpha$ ,5 $\alpha$ ,6 $\beta$ )-3-azabicyclo[3.1.0]hex-6-yl-4-fluoro- $\alpha$ -(4-fluorophenyl)- $\alpha$ -propoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 741676-11-9

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of azabicyclohexanes as muscarinic receptor antagonists)

RN 741676-11-9 CAPLUS

CN Benzenepropanamide, N-(1 $\alpha$ ,5 $\alpha$ ,6 $\beta$ )-3-azabicyclo[3.1.0]hex-6-yl- $\beta$ , $\beta$ -diphenyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 712355-53-8P 712355-57-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of azabicyclohexanes as muscarinic receptor antagonists)

RN 712355-53-8 CAPLUS

CN Benzeneacetamide, 4-fluoro- $\alpha$ -(4-fluorophenyl)- $\alpha$ -hydroxy-N-  
[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-  
yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712355-57-2 CAPLUS

CN Benzeneacetamide, 4-fluoro- $\alpha$ -(4-fluorophenyl)-N-  
[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-  
yl]- $\alpha$ -propoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:648506 CAPLUS

DOCUMENT NUMBER: 141:190686

TITLE: Preparation of 3,6-disubstituted azabicyclohexanes as muscarinic receptor antagonists

INVENTOR(S): Mehta, Anita; Silamkoti, Arundutt V.; Kumar, Naresh; Gupta, Jang Bahadur

PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India

SOURCE: PCT Int. Appl., 115 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 2004067510 A1 20040812 WO 2003-IB256 20030128  
 WO 2004067510 C1 20050324  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 AU 2003202727 A1 20040823 AU 2003-202727 20030128  
 EP 1590325 A1 20051102 EP 2003-701638 20030128  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 PRIORITY APPLN. INFO.: WO 2003-IB256 A 20030128  
 OTHER SOURCE(S): CASREACT 141:190686; MARPAT 141:190686  
 GI




AB Title compds. [I; Ar = (substituted) aryl, heteroaryl; R1 = H, OH, HOCH2, alkyl, amino, alkoxy, cycloalkyl, carbamoyl, halo, aryl; R2 = alkyl, cycloalkyl, cycloalkenyl, (substituted) aryl, heteroaryl; W = (CH2)p; p = 0, 1; X = O, S, NR, null; Y = CHR5CO; R5 = H, Me, (CH2)q; q = 0-4; Q = (CH2)m; m = 0-2; R3 = H, alkyl, CO2CMe3; R4 = (unsatd.) (substituted) aliphatic], were prepared Thus, 5-bromo-4-methylpent-3-ene, (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-6-tert-butoxycarbonylamino-3-azabicyclo[3.1.0]hexane, and K2CO3 were refluxed 5 h in MeCN to give (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-N-3-(4-methyl-3-pentenyl)-6-tert-butoxycarbonylamino-3-azabicyclo[3.1.0]hexane. This was treated with aqueous HCl in EtOAc at 0° to give (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-N-3-(4-methyl-3-pentenyl)-6-amino-3-azabicyclo[3.1.0]hexane. The latter was stirred with 2-hydroxy-2-cyclopentyl-2-(4-methoxyphenyl)acetic acid, hydroxybenzotriazole, N-methylmorpholine, and EDC.HCl in DMF at 0° to room temperature to give (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hex-6-yl]-2-hydroxy-2-cyclopentyl-2-(4-methoxyphenyl)acetamide. In a contractile assay using rat bladder strips, I showed pKB = 5.08-8.36 nM.

IT 738628-24-5P 738628-64-3P 738628-68-7P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (drug candidate; preparation of 3,6-disubstituted azabicyclohexanes as muscarinic receptor antagonists)

RN 738628-24-5 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[(3-nitrophenyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-64-3 CAPLUS

CN Benzoic acid, 4-[[ (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-6-  
[(cyclopentylhydroxyphenylacetyl)amino]-3-azabicyclo[3.1.0]hex-3-  
yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-68-7 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane-3-acetic acid, (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-6-  
[(cyclopentylhydroxyphenylacetyl)amino]- $\alpha$ -methyl-, ethyl ester (9CI)  
(CA INDEX NAME)

Relative stereochemistry.



IT	712356-14-4P	712356-15-5P	712356-64-4P
	712357-03-4P	738628-09-6P	738628-10-9P
	738628-11-0P	738628-12-1P	738628-13-2P
	738628-14-3P	738628-15-4P	738628-16-5P
	738628-17-6P	738628-18-7P	738628-19-8P
	738628-20-1P	738628-21-2P	738628-22-3P
	738628-23-4P	738628-25-6P	738628-26-7P
	738628-27-8P	738628-28-9P	738628-29-0P
	738628-30-3P	738628-31-4P	738628-32-5P
	738628-33-6P	738628-34-7P	738628-35-8P
	738628-36-9P	738628-37-0P	738628-38-1P
	738628-39-2P	738628-40-5P	738628-41-6P
	738628-42-7P	738628-43-8P	738628-44-9P
	738628-45-0P	738628-46-1P	738628-47-2P
	738628-48-3P	738628-49-4P	738628-50-7P
	738628-51-8P	738628-52-9P	738628-53-0P
	738628-54-1P	738628-55-2P	738628-56-3P
	738628-57-4P	738628-58-5P	738628-59-6P
	738628-60-9P	738628-61-0P	738628-62-1P

738628-63-2P 738628-65-4P 738628-66-5P  
 738628-67-6P 738628-69-8P 738628-70-1P  
 738628-71-2P 738628-72-3P 738628-73-4P  
 738628-74-5P 738628-75-6P 738628-76-7P  
 738628-77-8P 738628-78-9P 738628-79-0P  
 738628-80-3P 738628-81-4P 738628-82-5P  
 738628-83-6P 738628-84-7P 738628-85-8P  
 738628-86-9P 738628-87-0P 738628-88-1P  
 738628-89-2P 738628-90-5P 738628-91-6P  
 738628-92-7P 738628-93-8P 738628-94-9P  
 738628-95-0P 738628-96-1P 738628-97-2P  
 738628-98-3P 738628-99-4P 738629-00-0P  
 738629-01-1P 738629-02-2P 738629-03-3P  
 738629-04-4P 738629-05-5P 738629-06-6P  
 738629-07-7P 738629-08-8P 738629-09-9P  
 738629-10-2P 738629-11-3P 738629-12-4P  
 738629-13-5P 738629-14-6P 738629-15-7P  
 738629-16-8P 738629-17-9P 738629-18-0P  
 738629-19-1P 738629-20-4P 738629-21-5P  
 738629-22-6P 738629-23-7P 738629-24-8P  
 738629-25-9P 738629-26-0P 738629-27-1P  
 738629-28-2P 738629-44-2P 738629-45-3P  
 738629-46-4P 738629-47-5P 738629-48-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of 3,6-disubstituted azabicyclohexanes as muscarinic receptor antagonists)

RN 712356-14-4 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-15-5 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 712356-64-4 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclobutyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)

yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712357-03-4 CAPLUS

CN Benzeneacetamide,  $\alpha$ -phenyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-09-6 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-4-methoxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-10-9 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(2-thienylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-11-0 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(2-thienylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-12-1 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[(5-nitro-2-furanyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-13-2 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(4-methylpentyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-14-3 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-15-4 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-  
[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[2-(3,4,5-trimethoxyphenyl)ethyl]-3-  
azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-16-5 CAPLUS

CN Benzeneacetamide, N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[3-(1,3-benzodioxol-5-  
yl)propyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -cyclopentyl- $\alpha$ -  
hydroxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 738628-17-6 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-  
[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[(3,4,5-trimethoxyphenyl)methyl]-3-  
azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.






RN 738628-18-7 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[(3,5-dimethoxyphenyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-19-8 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[(3,4-dimethoxyphenyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-20-1 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[(3-methoxyphenyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 738628-21-2 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-

[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[[4-(trifluoromethyl)phenyl]methyl]-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-22-3 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[(5-methyl-2-furanyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-23-4 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[2-(4-methylphenoxy)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-25-6 CAPLUS


CN Benzeneacetamide, N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[2-(4-chlorophenyl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -cyclopentyl- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 738628-26-7 CAPLUS  
CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-  
[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[(4-nitrophenyl)methyl]-3-  
azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 738628-27-8 CAPLUS  
CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-  
[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(3-phenylpropyl)-3-azabicyclo[3.1.0]hex-6-  
yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 738628-28-9 CAPLUS  
CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-  
[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[(3-hydroxyphenyl)methyl]-3-  
azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 738628-29-0 CAPLUS  
CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-  
[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(1-phenylethyl)-3-azabicyclo[3.1.0]hex-6-  
yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-30-3 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[[4-(1,1-dimethylethyl)phenyl]methyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-31-4 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(2-quinolinylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-32-5 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[(4-methoxy-3-nitrophenyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 738628-33-6 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[(4-hydroxy-3-nitrophenyl)methyl]-3-

azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-34-7 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[(3,4-dichlorophenyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-35-8 CAPLUS

CN Benzeneacetamide, N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[(3-aminophenyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -cyclopentyl- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-36-9 CAPLUS

CN Benzeneacetamide, N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[(6-amino-2-pyridinyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -cyclopentyl- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-37-0 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-  
[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(2-phenoxyethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry. .



RN 738628-38-1 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-  
[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(3-phenoxypropyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-39-2 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-  
[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(1H-pyrrol-2-ylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-40-5 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-  
[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]-  
 $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-41-6 CAPLUS

CN Benzeneacetamide, N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[2-(1,3-benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -cyclobutyl- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-42-7 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopropyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-43-8 CAPLUS

CN Benzeneacetamide, N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[2-(1,3-benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -cyclopropyl- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 738628-44-9 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopropyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[(4-hydroxy-3-methoxyphenyl)methyl]-3-

azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-45-0 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-  
[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[(3-hydroxy-4-methoxyphenyl)methyl]-3-  
azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-46-1 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane-3-acetic acid, 6-[(cyclopentylhydroxyphenylacetyl)amino]- $\alpha$ -phenyl-, ethyl ester, (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )- (9CI)  
(CA INDEX NAME)

Relative stereochemistry.




RN 738628-47-2 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-  
[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[1-(2-hydroxyphenyl)ethyl]-3-  
azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.






RN 738628-48-3 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-  
[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[1-(4-methylphenyl)ethyl]-3-  
azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-49-4 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-  
[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenyl-3-pyridinylmethyl)-3-  
azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-50-7 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-  
[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(4-pyridinylmethyl)-3-azabicyclo[3.1.0]hex-  
6-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 738628-51-8 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-

(2,3-dihydro-1H-inden-1-yl)-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -hydroxy-  
(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-52-9 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-  
[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[(3-methylphenyl)methyl]-3-  
azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-53-0 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-  
[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[(2,4,6-trimethylphenyl)methyl]-3-  
azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-54-1 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[2-  
(3,4-dimethoxyphenyl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -hydroxy-  
(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-55-2 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[2-(3,4-dimethylphenyl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-56-3 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-pentyl-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-57-4 CAPLUS

CN Benzeneacetamide, N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[(4-cyanophenyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -cyclopentyl- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-58-5 CAPLUS

CN Benzeneacetamide, N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[(2-cyanophenyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -cyclopentyl- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-59-6 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[(pentafluorophenyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-60-9 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(3-pyridinylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 738628-61-0 CAPLUS

CN Benzeneacetamide, N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[(4-bromo-2-

thienyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -cyclohexyl- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-62-1 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(1-phenylethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-63-2 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[(2-nitrophenyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-65-4 CAPLUS


CN Benzeneacetamide,  $\alpha$ -cyclopentyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(diphenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 738628-66-5 CAPLUS  
 CN Benzoic acid, 4-[[ (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-6-  
 [(cyclopentylhydroxyphenylacetyl)amino]-3-azabicyclo[3.1.0]hex-3-  
 yl)methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 738628-67-6 CAPLUS  
 CN Benzeneacetamide, N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-[(2-  
 aminophenyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -cyclopentyl-  
 $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 738628-69-8 CAPLUS  
 CN Benzeneacetamide, N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-[2-(4-  
 acetylphenyl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -cyclopentyl-  
 $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 738628-70-1 CAPLUS  
 CN Benzoic acid, 4-[2-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-6-  
 [(cyclopentylhydroxyphenylacetyl)amino]-3-azabicyclo[3.1.0]hex-3-yl]ethyl]-  
 , methyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-71-2 CAPLUS

CN Benzeneacetamide, N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[(3-cyanophenyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -cyclopentyl- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-72-3 CAPLUS

CN Benzeneacetamide, N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[(2-cyanophenyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -cyclohexyl- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-73-4 CAPLUS


CN Benzeneacetamide, N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[(3-cyanophenyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -cyclohexyl- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 738628-74-5 CAPLUS  
 CN Benzeneacetamide,  $\alpha$ -cyclohexyl- $\alpha$ -hydroxy-N-  
 [(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(3-methylbutyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 738628-75-6 CAPLUS  
 CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-  
 [(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[2-[4-(hydroxymethyl)phenyl]ethyl]-3-  
 azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 738628-76-7 CAPLUS  
 CN Benzeneacetamide, N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[(4-amino-3-  
 fluorophenyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -cyclopentyl-  
 $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-77-8 CAPLUS  
 CN Benzeneacetamide,  $\alpha$ -cyclopentyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[1-  
 (3,4-dimethylphenyl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -hydroxy-  
 (9CI) (CA INDEX NAME)

Relative stereochemistry.






RN 738628-78-9 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-  
[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[2-(3-methylphenoxy)ethyl]-3-  
azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-79-0 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-  
[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[3-(3-methylphenoxy)propyl]-3-  
azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-80-3 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-  
[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[(2-methylphenyl)methyl]-3-  
azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-81-4 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-  
 [(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[2-(2-methylphenyl)ethyl]-3-  
 azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-82-5 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-  
 (1,3-dioxolan-2-ylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -hydroxy-  
 (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-83-6 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane-3-acetic acid, 6-[(cyclopentylhydroxyphenylacetyl)amino]- $\alpha$ -methyl-, (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-84-7 CAPLUS

CN Benzeneacetamide,  $\alpha$ -hydroxy- $\alpha$ -phenyl-N-  
 [(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(1-phenylethyl)-3-azabicyclo[3.1.0]hex-6-  
 yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-85-8 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopropyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[2-(2,3-dihydro-5-benzofuranyl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-86-9 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopropyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(1-phenylethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-87-0 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclobutyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(1-phenylethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-88-1 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane-3-acetic acid, 6-[(cycloheptylhydroxyphenylacetyl)amino]- $\alpha$ -phenyl-, (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-89-2 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[2-(1H-indol-3-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-90-5 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(2-naphthalenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-91-6 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[2-(1H-indol-3-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-92-7 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-hexyl-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-93-8 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(1,2,3,4-tetrahydro-1-naphthalenyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-94-9 CAPLUS


CN Benzeneacetamide, N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[(2-chlorophenyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -cyclopentyl- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 738628-95-0 CAPLUS  
CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-  
[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[2-(2-methoxyphenyl)ethyl]-3-  
azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 738628-96-1 CAPLUS  
CN Benzeneacetamide,  $\alpha$ -cyclopentyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[2-  
(4-fluorophenyl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -hydroxy- (9CI)  
(CA INDEX NAME)

Relative stereochemistry.




RN 738628-97-2 CAPLUS  
CN Benzeneacetamide,  $\alpha$ -cyclopentyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[1-  
(2,3-dihydro-1H-inden-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -  
hydroxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 738628-98-3 CAPLUS  
CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-  
[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[1-(1-naphthalenyl)ethyl]-3-  
azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738628-99-4 CAPLUS

CN Benzeneacetamide, N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[1-(1,3-benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -cyclopentyl- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738629-00-0 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[1-(5,6,7,8-tetrahydro-2-naphthalenyl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 738629-01-1 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopropyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(3Z)-3-hexenyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 738629-02-2 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopropyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(3E)-3-hexenyl-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.  
Double bond geometry as shown.



RN 738629-03-3 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(3E)-3-hexenyl-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.  
Double bond geometry as shown.



RN 738629-04-4 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(3Z)-3-hexenyl-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.  
Double bond geometry as shown.




RN 738629-05-5 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(3E)-3-hexenyl-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.  
Double bond geometry as shown.






RN 738629-06-6 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(3Z)-3-hexenyl-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 738629-07-7 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(2-naphthalenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738629-08-8 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(1-methyl-2-oxo-2-phenylethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 738629-09-9 CAPLUS

CN Benzeneacetamide, N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[2-[4-(aminocarbonyl)phenyl]ethyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -

cyclopentyl- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738629-10-2 CAPLUS

CN Benzoic acid, 4-[2-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-6-[(cyclopentylhydroxyphenylacetyl)amino]-3-azabicyclo[3.1.0]hex-3-yl]ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738629-11-3 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(2-methyl-1-phenylpropyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738629-12-4 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(1-methyl-2-oxo-2-phenylethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738629-13-5 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-hexyl-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738629-14-6 CAPLUS

CN Benzeneacetamide, N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[2-(4-cyanophenyl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -cyclopentyl- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738629-15-7 CAPLUS


CN Benzeneacetamide, N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[2-[4-(aminosulfonyl)phenyl]ethyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -cyclopentyl- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 738629-16-8 CAPLUS  
CN Benzeneacetamide, N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(cyclohexylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -cyclopentyl- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 738629-17-9 CAPLUS  
CN Benzeneacetamide,  $\alpha$ -chloro- $\alpha$ -cyclohexyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 738629-18-0 CAPLUS  
CN Benzeneacetamide,  $\alpha$ -cyclohexyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 738629-19-1 CAPLUS  
CN Benzeneacetamide,  $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738629-20-4 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738629-21-5 CAPLUS

CN Benzeneacetamide,  $\alpha$ -hydroxy- $\alpha$ -methyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738629-22-6 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-methyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(1-phenylethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738629-23-7 CAPLUS

CN Benzeneacetamide, N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[2-(1,3-benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738629-24-8 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-methyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738629-25-9 CAPLUS

CN Benzeneacetamide, N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[2-(1,3-benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -cyclohexyl- $\alpha$ -hydroxy-N-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738629-26-0 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl- $\alpha$ -hydroxy-N-methyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738629-27-1 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-methyl-N-  
 [(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(4-methyl-3-pentenyl)-3-  
 azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 738629-28-2 CAPLUS


CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-methyl-N-  
 [(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(4-methyl-3-pentenyl)-3-  
 azabicyclo[3.1.0]hex-6-yl]-, (2R,3R)-2,3-dihydroxybutanedioate (salt)  
 (9CI) (CA INDEX NAME)

CM 1

CRN 738629-27-1

CMF C25 H36 N2 O2

Relative stereochemistry.




CM 2

CRN 87-69-4

CMF C4 H6 O6


Absolute stereochemistry.



RN 738629-44-2 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclobutyl- $\alpha$ -hydroxy-N-  
 [(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(4-methylpentenyl)-3-azabicyclo[3.1.0]hex-6-  
 yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738629-45-3 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopropyl- $\alpha$ -hydroxy-4-methoxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738629-46-4 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[(4-hydroxy-3-methoxyphenyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 738629-47-5 CAPLUS

CN Benzeneacetamide, N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[(4-bromo-2-thienyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -cyclopentyl- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.






RN 738629-48-6 CAPLUS

CN Cycloheptaneacetamide,  $\alpha$ -hydroxy- $\alpha$ -phenyl-N-  
[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(1-phenylethyl)-3-azabicyclo[3.1.0]hex-6-  
yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 712355-73-2 712356-39-3 712356-40-6  
712356-41-7 712356-42-8 738629-41-9  
738629-42-0


RL: RCT (Reactant); RACT (Reactant or reagent)

```
(preparation of 3,6-disubstituted azabicyclohexanes as muscarinic receptor antagonists)
```

RN 712355-73-2 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl- $\alpha$ -hydroxy-N-  
[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-39-3 CAPLUS


CN Benzeneacetamide, N-(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl- $\alpha$ -cyclopentyl- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 712356-40-6 CAPLUS  
 CN Cycloheptaneacetamide, N-(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl- $\alpha$ -hydroxy- $\alpha$ -phenyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 712356-41-7 CAPLUS  
 CN Benzeneacetamide, N-(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl- $\alpha$ -cyclobutyl- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 712356-42-8 CAPLUS  
 CN Benzeneacetamide, N-(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl- $\alpha$ -cyclopropyl- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 738629-41-9 CAPLUS  
 CN Carbamic acid, [4-[[[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-6-[(cyclopentylhydroxyphenylacetyl)amino]-3-azabicyclo[3.1.0]hex-3-yl]methyl]-2-fluorophenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738629-42-0 CAPLUS

CN Benzeneacetamide, N-[(1α,5α,6α)-3-azabicyclo[3.1.0]hex-6-yl]-α-hydroxy-α-phenyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 712356-35-9P 738629-31-7P 738629-32-8P

738629-33-9P 738629-34-0P 738629-35-1P

738629-36-2P 738629-37-3P 738629-38-4P

738629-39-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 3,6-disubstituted azabicyclohexanes as muscarinic receptor antagonists)

RN 712356-35-9 CAPLUS

CN Benzeneacetamide, N-(1α,5α,6α)-3-azabicyclo[3.1.0]hex-6-yl]-α-cyclohexyl-α-hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738629-31-7 CAPLUS

CN Carbamic acid, [6-[[[(1α,5α,6α)-6-[(cyclopentylhydroxyphenylacetyl)amino]-3-azabicyclo[3.1.0]hex-3-yl]methyl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738629-32-8 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-  
[(cyclopentylhydroxyphenylacetyl)amino]-, 1,1-dimethylethyl ester,  
(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738629-33-9 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-  
[[cyclopentylphenyl[(trimethylsilyl)oxy]acetyl]amino]-, 1,1-dimethylethyl  
ester, (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 738629-34-0 CAPLUS


CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-  
[(cyclopentylhydroxyphenylacetyl)methylamino]-, 1,1-dimethylethyl ester,  
(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 738629-35-1 CAPLUS  
 CN Benzeneacetamide, N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-methyl-, monohydrochloride (9CI)  
 (CA INDEX NAME)


Relative stereochemistry.



● HCl


RN 738629-36-2 CAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-[(cyclohexylhydroxyphenylacetyl)amino]-, 1,1-dimethylethyl ester, (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 738629-37-3 CAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-[[cyclohexylphenyl[(trimethylsilyl)oxy]acetyl]amino]-, 1,1-dimethylethyl ester, (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 738629-38-4 CAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-  
 [[cyclohexylphenyl[(trimethylsilyl)oxy]acetyl]methylamino]-,  
 1,1-dimethylethyl ester, (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )- (9CI) (CA INDEX  
 NAME)

Relative stereochemistry.



RN 738629-39-5 CAPLUS  
 CN Benzeneacetamide, N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -cyclohexyl- $\alpha$ -hydroxy-N-methyl-, monohydrochloride (9CI)  
 (CA INDEX NAME)

Relative stereochemistry.




● HCl

L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2004:515483 CAPLUS  
 DOCUMENT NUMBER: 141:71449  
 TITLE: Preparation of 3,6-disubstituted  
 azabicyclo[3.1.0]hexane derivatives as muscarinic  
 receptor antagonists  
 INVENTOR(S): Mehta, Anita; Silamkoti, Arundutt Viswanatham;  
 Miriyala, Bruhaspathy; Arora, Sudershan Kumar;  
 Srinivasulu, Boju; Mukherjee, Bireshwar; Gupta, Jang  
 Bahadur  
 PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India  
 SOURCE: PCT Int. Appl., 118 pp.  
 CODEN: PIXXD2

DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004052857	A1	20040624	WO 2002-IB5220	20021210
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002353286	A1	20040630	AU 2002-353286	20021210
EP 1572648	A1	20050914	EP 2002-788307	20021210
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2006518707	T2	20060817	JP 2004-558864	20021210
PRIORITY APPLN. INFO.:			WO 2002-IB5220	A 20021210
OTHER SOURCE(S):			CASREACT 141:71449; MARPAT 141:71449	

GI



AB Title compds. I (Ar = aryl, heteroaryl, etc.; R1cycloalkyl, cycloalkenyl, aryl, heteroaryl, etc.; R2 = H, OH, amino, alkoxy, alkenyloxy, alkynyloxy, carbamoyl, halo; W = (CH2)p; p = 0, 1; X = O, S, amino, no atom; Y = (CHR5)qCO, R5 = H, Me; (CH2)q; q = 0-4; m = 0-2; R3 = H, alkyl, CO2Bu-t; R4 = H, alkyl, etc.) and their pharmaceutically acceptable salts are prepared. The compds. of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to pharmaceutical compns. containing the compds. of the present invention and the methods for treating the diseases mediated through muscarinic receptors.


IT 712355-73-2P 712356-00-8P 712356-14-4P  
 712356-22-4P 712356-31-5P 712356-48-4P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of 3,6-disubstituted azabicyclohexane derivs. as muscarinic receptor antagonists)

RN 712355-73-2 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl- $\alpha$ -hydroxy-N-  
 [(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-00-8 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl- $\alpha$ -hydroxy-4-methyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-14-4 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-22-4 CAPLUS

CN Cyclooctaneacetamide,  $\alpha$ -hydroxy- $\alpha$ -phenyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 712356-31-5 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-



[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hex-6-yl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 712356-48-4 CAPLUS

CN Benzeneacetamide, N-(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl- $\alpha$ -cyclohexyl- $\alpha$ -methoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 712355-74-3P 712355-75-4P 712355-78-7P  
 712355-79-8P 712355-80-1P 712355-81-2P  
 712355-85-6P 712355-88-9P 712355-91-4P  
 712355-92-5P 712355-99-2P 712356-02-0P  
 712356-05-3P 712356-07-5P 712356-15-5P  
 712356-16-6P 712356-17-7P 712356-18-8P  
 712356-19-9P 712356-20-2P 712356-32-6P  
 712356-35-9P 712356-36-0P 712356-37-1P  
 712356-38-2P 712356-39-3P 712356-40-6P  
 712356-41-7P 712356-42-8P 712356-43-9P  
 712356-44-0P 712356-45-1P 712356-46-2P  
 712357-04-5P 712357-05-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3,6-disubstituted azabicyclohexane derivs. as muscarinic receptor antagonists)

RN 712355-74-3 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-[(3,5-difluorophenyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712355-75-4 CAPLUS

CN Benzeneacetamide, N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-[(4-bromophenyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -cyclohexyl- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712355-78-7 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-[2-(2,3-dihydro-5-benzofuranyl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712355-79-8 CAPLUS

CN Benzeneacetamide, N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-[2-(1,3-benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -cyclohexyl- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712355-80-1 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-[(2,3-dihydro-5-benzofuranyl)acetyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712355-81-2 CAPLUS

CN Benzeneacetamide, N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[2-(5-benzofuranyl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -cyclohexyl- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712355-85-6 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(2-propynyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712355-88-9 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-cyclopropyl-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712355-91-4 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712355-92-5 CAPLUS

CN Benzeneacetamide, N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(1,3-benzodioxol-5-ylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -cyclohexyl- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712355-99-2 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane-3-carboxamide, 6-[(cyclohexylhydroxyphenylacetyl)amino]-N-[(4-methylphenyl)sulfonyl]-, (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-02-0 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl- $\alpha$ -hydroxy-4-phenoxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-05-3 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl-4-(1,1-dimethylethyl)- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-07-5 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl- $\alpha$ -hydroxy-4-methoxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-15-5 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-16-6 CAPLUS

CN Benzeneacetamide, N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[2-(1,3-benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -cyclopentyl- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-17-7 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(2-phenylethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-18-8 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[2-(2,3-dihydro-5-benzofuranyl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 712356-19-9 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[(6-methyl-2-pyridinyl)methyl]-3-

azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-20-2 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopentyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[(2,3-dihydro-5-benzofuranyl)acetyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-32-6 CAPLUS

CN Benzeneacetamide, N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[2-(1,3-benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 712356-35-9 CAPLUS

CN Benzeneacetamide, N-(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl- $\alpha$ -cyclohexyl- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-36-0 CAPLUS

CN Benzeneacetamide, N-(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl- $\alpha$ -cyclohexyl-4-fluoro- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-37-1 CAPLUS

CN Benzeneacetamide, N-(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl- $\alpha$ -cyclohexyl- $\alpha$ -hydroxy-4-methoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 712356-38-2 CAPLUS

CN Benzeneacetamide, N-(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl- $\alpha$ -cyclohexyl- $\alpha$ -hydroxy-4-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.






RN 712356-39-3 CAPLUS

CN Benzeneacetamide, N-(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl- $\alpha$ -cyclopentyl- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-40-6 CAPLUS

CN Cycloheptaneacetamide, N-(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl- $\alpha$ -hydroxy- $\alpha$ -phenyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-41-7 CAPLUS

CN Benzeneacetamide, N-(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl- $\alpha$ -cyclobutyl- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-42-8 CAPLUS

CN Benzeneacetamide, N-(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl- $\alpha$ -cyclopropyl- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-43-9 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -cyclohexyl- $\alpha$ -hydroxy-,  
2-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-ylamino]-2-  
oxoethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-44-0 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -cyclohexyl- $\alpha$ -hydroxy-,  
2-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-ylamino]-1-methyl-  
2-oxoethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-45-1 CAPLUS

CN Benzeneacetic acid, 4-fluoro- $\alpha$ -(4-fluorophenyl)- $\alpha$ -hydroxy-,  
4-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl[(1,1-  
dimethylethoxy)carbonyl]amino]butyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-46-2 CAPLUS

CN Benzeneacetic acid, 4-fluoro- $\alpha$ -(4-fluorophenyl)- $\alpha$ -propoxy-,  
4-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl[(1,1-  
dimethylethoxy)carbonyl]amino]butyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712357-04-5 CAPLUS

CN Benzeneacetamide, N-(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-  
yl- $\alpha$ -phenyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712357-05-6 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-  
[(2,6-difluorophenyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -hydroxy-  
(9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 712356-62-2P 712356-64-4P 712356-66-6P

712356-67-7P 712357-03-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

```
(preparation of 3,6-disubstituted azabicyclohexane derivs. as muscarinic
receptor antagonists)
```

RN 712356-62-2 CAPLUS

CN Cycloheptaneacetamide,  $\alpha$ -hydroxy- $\alpha$ -phenyl-N-  
[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-  
yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-64-4 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclobutyl- $\alpha$ -hydroxy-N-  
[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-66-6 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclopropyl- $\alpha$ -hydroxy-N-  
[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-67-7 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -cyclohexyl- $\alpha$ -hydroxy-,  
2-oxo-2-[[ (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ ) -3- (phenylmethyl) -3-  
azabicyclo[3.1.0]hex-6-yl]amino]ethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712357-03-4 CAPLUS

CN Benzeneacetamide,  $\alpha$ -phenyl-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ ) -3-  
(phenylmethyl) -3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 712355-66-3P 712355-67-4P 712355-97-0P  
712356-01-9P 712356-03-1P 712356-09-7P


RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);  
BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);  
USES (Uses)

(preparation of 3,6-disubstituted azabicyclohexane derivs. as muscarinic  
receptor antagonists)

RN 712355-66-3 CAPLUS

CN Benzeneacetic acid, 4-fluoro- $\alpha$ -(4-fluorophenyl)- $\alpha$ -hydroxy-,  
4-[[ (1, 1-dimethylethoxy) carbonyl] [(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ ) -3-  
(phenylmethyl) -3-azabicyclo[3.1.0]hex-6-yl]amino]butyl ester (9CI) (CA  
INDEX NAME)


Relative stereochemistry.



RN 712355-67-4 CAPLUS

CN Benzeneacetic acid, 4-fluoro- $\alpha$ -(4-fluorophenyl)- $\alpha$ -propoxy-,  
4-[[[(1,1-dimethylethoxy)carbonyl][(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-  
(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]amino]butyl ester (9CI) (CA  
INDEX NAME)


Relative stereochemistry.



RN 712355-97-0 CAPLUS

CN Benzoic acid, 4-[[[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-6-  
[(cyclohexylhydroxyphenylacetyl)amino]-3-azabicyclo[3.1.0]hex-3-  
yl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-01-9 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl- $\alpha$ -hydroxy-4-methoxy-N-  
[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-03-1 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl-4-fluoro- $\alpha$ -hydroxy-N-  
[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-09-7 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl- $\alpha$ -methoxy-N-  
[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 712355-52-7P 712355-53-8P 712355-54-9P  
712355-55-0P 712355-56-1P 712355-57-2P  
712355-58-3P 712355-59-4P 712355-60-7P  
712355-61-8P 712355-62-9P 712355-63-0P  
712355-64-1P 712355-65-2P 712355-68-5P  
712355-69-6P 712355-70-9P 712355-71-0P  
712355-72-1P 712355-76-5P 712355-77-6P  
712355-82-3P 712355-83-4P 712355-84-5P

712355-86-7P 712355-87-8P 712355-89-0P  
 712355-90-3P 712355-93-6P 712355-94-7P  
 712355-95-8P 712355-96-9P 712355-98-1P  
 712356-04-2P 712356-06-4P 712356-08-6P  
 712356-10-0P 712356-11-1P 712356-12-2P  
 712356-13-3P 712356-21-3P 712356-23-5P  
 712356-24-6P 712356-25-7P 712356-26-8P  
 712356-27-9P 712356-28-0P 712356-29-1P  
 712356-30-4P 712356-33-7P 712356-34-8P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3,6-disubstituted azabicyclohexane derivs. as muscarinic receptor antagonists)

RN 712355-52-7 CAPLUS

CN Benzeneacetamide,  $\alpha$ -hydroxy- $\alpha$ -phenyl-N-  
 [(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712355-53-8 CAPLUS

CN Benzeneacetamide, 4-fluoro- $\alpha$ -(4-fluorophenyl)- $\alpha$ -hydroxy-N-  
 [(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 712355-54-9 CAPLUS

CN Benzeneacetamide,  $\alpha$ -phenyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-  
 (phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -(2-propenyloxy)- (9CI)  
 (CA INDEX NAME)

Relative stereochemistry.






RN 712355-55-0 CAPLUS

CN Benzeneacetamide, 4-fluoro- $\alpha$ -(4-fluorophenyl)-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -(2-propenyloxy)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712355-56-1 CAPLUS

CN Benzeneacetamide,  $\alpha$ -phenyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -propoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712355-57-2 CAPLUS

CN Benzeneacetamide, 4-fluoro- $\alpha$ -(4-fluorophenyl)-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -propoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712355-58-3 CAPLUS

CN Benzeneacetamide,  $\alpha$ -phenyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -(2-propynyloxy)- (9CI)  
(CA INDEX NAME)


Relative stereochemistry.



RN 712355-59-4 CAPLUS

CN 2-Furanacetamide,  $\alpha$ -2-furanyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI)  
(CA INDEX NAME)


Relative stereochemistry.



RN 712355-60-7 CAPLUS

CN 2-Thiopheneacetamide,  $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -2-thienyl- (9CI)  
(CA INDEX NAME)


Relative stereochemistry.



RN 712355-61-8 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -hydroxy- $\alpha$ -phenyl-, 4-[[[(1,1-dimethylethoxy)carbonyl][(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]amino]butyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712355-62-9 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -hydroxy- $\alpha$ -phenyl-, 3-[[[(1,1-dimethylethoxy)carbonyl][(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]amino]propyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712355-63-0 CAPLUS


CN Benzeneacetic acid,  $\alpha$ -phenyl- $\alpha$ -propoxy-, 3-[[[(1,1-dimethylethoxy)carbonyl][(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]amino]propyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 712355-64-1 CAPLUS  
 CN Benzeneacetic acid,  $\alpha$ -phenyl- $\alpha$ -propoxy-, 4-[[ (1,1-dimethylethoxy) carbonyl] [ (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]amino]butyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 712355-65-2 CAPLUS  
 CN Benzeneacetic acid,  $\alpha$ -phenyl- $\alpha$ -(2-propenyloxy)-, 4-[[ (1,1-dimethylethoxy) carbonyl] [ (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]amino]butyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 712355-68-5 CAPLUS  
 CN Benzeneacetic acid,  $\alpha$ -phenyl- $\alpha$ -propoxy-, 2-oxo-2-[[ (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]amino]ethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 712355-69-6 CAPLUS  
 CN Benzeneacetic acid,  $\alpha$ -phenyl- $\alpha$ -(2-propenyloxy)-, 2-oxo-2-[[ (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]amino]ethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712355-70-9 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -phenyl- $\alpha$ -(2-propenyloxy)-, 3-oxo-3-[[ (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]amino]propyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712355-71-0 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -phenyl- $\alpha$ -propoxy-, 3-oxo-3-[[ (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]amino]propyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712355-72-1 CAPLUS


CN Benzeneacetic acid, 4-fluoro- $\alpha$ -(4-fluorophenyl)- $\alpha$ -hydroxy-, 2-oxo-2-[[ (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]amino]ethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 712355-76-5 CAPLUS  
CN Benzeneacetamide, N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-([1,1'-biphenyl]-2-ylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -cyclohexyl- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 712355-77-6 CAPLUS  
CN Benzeneacetamide,  $\alpha$ -cyclohexyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(2-phenylethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 712355-82-3 CAPLUS  
CN Benzeneacetamide,  $\alpha$ -cyclohexyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-methyl-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 712355-83-4 CAPLUS  
CN Benzeneacetamide,  $\alpha$ -cyclohexyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-ethyl-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712355-84-5 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl- $\alpha$ -hydroxy-N-  
[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-propyl-3-azabicyclo[3.1.0]hex-6-yl]- (9CI)  
(CA INDEX NAME)


Relative stereochemistry.



RN 712355-86-7 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl- $\alpha$ -hydroxy-N-  
[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(2-propenyl)-3-azabicyclo[3.1.0]hex-6-yl]-  
(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712355-87-8 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl- $\alpha$ -hydroxy-N-  
[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(1-methylethyl)-3-azabicyclo[3.1.0]hex-6-yl]-  
(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712355-89-0 CAPLUS

CN Benzeneacetamide, N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-butyl-3-  
azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -cyclohexyl- $\alpha$ -hydroxy- (9CI) (CA  
INDEX NAME)


Relative stereochemistry.



RN 712355-90-3 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl- $\alpha$ -hydroxy-N-  
[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(3-methyl-2-butenyl)-3-  
azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712355-93-6 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-  
(6,6-dimethyl-2,4-heptadiynyl)-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -  
hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712355-94-7 CAPLUS

CN Benzeneacetamide, N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-benzoyl-3-  
azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -cyclohexyl- $\alpha$ -hydroxy- (9CI) (CA  
INDEX NAME)

Relative stereochemistry.




RN 712355-95-8 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[(5-  
formyl-2-furanyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -hydroxy-



(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712355-96-9 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[(phenylamino)thioxomethyl]-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712355-98-1 CAPLUS

CN Benzoic acid, 4-[[[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-6-[(cyclohexylhydroxyphenylacetyl)amino]-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-04-2 CAPLUS

CN 1,3-Benzodioxole-5-acetamide,  $\alpha$ -cyclohexyl- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-06-4 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl- $\alpha$ -hydroxy-4-methyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-08-6 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl-4-fluoro- $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-10-0 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-ethyl-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -methoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-11-1 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -(2-propenyloxy)- (9CI)  
(CA INDEX NAME)


Relative stereochemistry.



RN 712356-12-2 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl- $\alpha$ -methoxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-13-3 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[(2,4-difluorophenyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -methoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 712356-21-3 CAPLUS

CN Benzeneacetamide, N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[2-(5-benzofuranyl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -cyclopentyl-

$\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-23-5 CAPLUS

CN Cyclooctaneacetamide,  $\alpha$ -hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hex-6-yl]- $\alpha$ -phenyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-24-6 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl- $\alpha$ -hydroxy-N-[1-methyl-2-oxo-2-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-25-7 CAPLUS

CN Benzeneacetamide,  $\alpha$ -cyclohexyl- $\alpha$ -hydroxy-N-[2-oxo-2-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-26-8 CAPLUS

CN Benzenacetamide,  $\alpha$ -cyclohexyl- $\alpha$ -hydroxy-N-[3-oxo-3-[[ (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]amino]propyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-27-9 CAPLUS

CN Benzenepropanamide,  $\beta$ -cyclohexyl- $\beta$ -hydroxy-N-[[ (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-28-0 CAPLUS

CN Benzenepropanamide,  $\beta$ -cyclohexyl- $\beta$ -hydroxy-N-[2-oxo-2-[[ (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]amino]ethyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 712356-29-1 CAPLUS

CN Benzenepropanamide,  $\beta$ -cyclohexyl- $\beta$ -hydroxy-N-[1-methyl-2-oxo-2-[[ (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-

yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 712356-30-4 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -cyclohexyl- $\alpha$ -hydroxy-,  
1-methyl-2-oxo-2-[[ (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(phenylmethyl)-3-  
azabicyclo[3.1.0]hex-6-yl]amino]ethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 712356-33-7 CAPLUS


CN Butanedioic acid, compd. with ( $\alpha$ R)- $\alpha$ -cyclopentyl- $\alpha$ -  
hydroxy-N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(4-methyl-3-pentenyl)-3-  
azabicyclo[3.1.0]hex-6-yl]benzeneacetamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 712356-31-5

CMF C24 H34 N2 O2

Absolute stereochemistry. Rotation (+).



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO<sub>2</sub>C-CH<sub>2</sub>-CH<sub>2</sub>-CO<sub>2</sub>H

RN 712356-34-8 CAPLUS


CN Benzeneacetamide,  $\alpha$ -cyclopentyl- $\alpha$ -hydroxy-N-

[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hex-6-yl]-, ( $\alpha$ R)-, (2R, 3R)-2, 3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 712356-31-5  
CMF C24 H34 N2 O2


Absolute stereochemistry. Rotation (+).



CM 2


CRN 87-69-4  
CMF C4 H6 O6

Absolute stereochemistry.



L4 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2003:492705 CAPLUS  
DOCUMENT NUMBER: 139:69253  
TITLE: Preparation of phenyl oxazolidinone derivatives as potential antimicrobials  
INVENTOR(S): Mehta, Anita; Arora, Sudershan K.; Das, Biswajit; Ray, Abhijit; Rudra, Sonali; Rattan, Ashok  
PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India  
SOURCE: U.S. Pat. Appl. Publ., 38 pp., Cont.-in-part of U.S. Ser. No. 906,215.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003119817	A1	20030626	US 2002-51784	20020117
US 6956040	B2	20051018		
US 2002103186	A1	20020801	US 2001-906215	20010716
US 6734307	B2	20040511		
PRIORITY APPLN. INFO.:			US 2001-906215	A2 20010716
			IN 2000-DE654	A 20000717
OTHER SOURCE(S):			CASREACT 139:69253; MARPAT 139:69253	
GI				



AB Substituted Ph oxazolidinones, e.g. of formula I [T = heterocyclic ring, aryl; R = alkyl, halo, CN, CHO, NH<sub>2</sub>, NO<sub>2</sub>, etc.; X = CH, CH-S, CH-O, N; Y, Z = H, alkyl, cycloalkyl, bridging group; U, V = alkyl, F, Cl, Br, etc.; W = CH<sub>2</sub>, CO, CH<sub>2</sub>NH, etc.; R<sub>1</sub> = NHCHR<sub>2</sub>, NR<sub>2</sub>CSR<sub>2</sub>; R<sub>2</sub> = H, alkyl, cycloalkyl, alkoxy, etc.], are prepared. This invention also relates to pharmaceutical compds. containing the compds. of the present invention as antimicrobials. The compds. are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including gram-pos. aerobic bacteria such as multiply-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms such as *Bacterioides* spp. and *Clostridia* spp. species, and acid fast organisms such as *Mycobacterium tuberculosis*, *Mycobacterium avium* and *Mycobacterium* spp. Thus, II was prepared and showed antibacterial activity against several strains.

IT 392659-92-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of Ph oxazolidinone derivs. as antibacterial agents)

RN 392659-92-6 CAPLUS

CN 2-Thiopheneacetamide, N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

43

THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



ACCESSION NUMBER: 2002:777935 CAPLUS  
 DOCUMENT NUMBER: 137:294960  
 TITLE: Preparation of 3-azolypropyloxyhydroxamic acids as procollagen c-proteinase (PCP) inhibitors  
 INVENTOR(S): Bailey, Simon; Fish, Paul Vincent; James, Kim; Whitlock, Gavin Alistair  
 PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.  
 SOURCE: PCT Int. Appl., 209 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002079200	A1	20021010	WO 2002-IB699	20020308
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2442481	AA	20021010	CA 2002-2442481	20020308
EP 1373264	A1	20040102	EP 2002-713078	20020308
EP 1373264	B1	20041222		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2002008499	A	20040420	BR 2002-8499	20020308
JP 2004524365	T2	20040812	JP 2002-577825	20020308
AT 285409	E	20050115	AT 2002-713078	20020308
ES 2232740	T3	20050601	ES 2002-2713078	20020308
US 2003069291	A1	20030410	US 2002-112338	20020329
US 6821972	B2	20041123		
PRIORITY APPLN. INFO.:			GB 2001-8102	A 20010330
			US 2001-293379P	P 20010524
			WO 2002-IB699	W 20020308

OTHER SOURCE(S): MARPAT 137:294960

AB HONHCOCH2CH(XR)QY [X = (fluoro-substituted) alkylene, alkenylene; R = (fluoro-substituted) aryl, cycloalkyl, cycloalkenyl; Q = oxazolyl, oxadiazolyl; Y = mono- or bicyclic unsatd. (substituted) (hetero)cycllyl], were prepared Thus, (3R)-6-cyclohexyl-3-[3-(2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)-1,2,4-oxadiazol-5-yl]hexanoic acid (preparation given) in THF was treated with Et3N, iso-Bu chloroformate, and O-trimethylsilylhydroxylamine at 0° followed by stirring at room temperature to give (3R)-6-cyclohexyl-3-[3-(2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)-1,2,4-oxadiazol-5-yl]-N-hydroxyhexanamide. Tested title compds. inhibited PCP with IC50≤1 μM.

IT 468733-18-8P 468733-19-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3-azolypropyloxyhydroxamic acids as procollagen c-proteinase inhibitors)

RN 468733-18-8 CAPLUS

CN Carbamic acid, [3-[5-[5-[(1R)-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl]-1,2,4-oxadiazol-3-yl]-2-pyridinyl]-3-azabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 468733-19-9 CAPLUS

CN 1,2,4-Oxadiazole-5-propanamide, 3-[6-(6-amino-3-azabicyclo[3.1.0]hex-3-yl)-3-pyridinyl]- $\beta$ -(3-cyclohexylpropyl)-N-hydroxy-, ( $\beta$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 468733-20-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of 3-azolypropylpropanohydroxamic acids as procollagen c-proteinase inhibitors)

RN 468733-20-2 CAPLUS

CN 1,2,4-Oxadiazole-5-propanoic acid,  $\beta$ -(3-cyclohexylpropyl)-3-[6-[6-[[[1,1-dimethylethoxy]carbonyl]amino]-3-azabicyclo[3.1.0]hex-3-yl]-3-pyridinyl]-, ( $\beta$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:72093 CAPLUS

DOCUMENT NUMBER: 136:134748

TITLE: Oxazolidinone derivatives as antimicrobials

INVENTOR(S): Mehta, Anita; Arora, Sudershan K.; Das, Biswajit; Ray, Abhijit; Rudra, Sonali; Rattan, Ashok



PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India

SOURCE: PCT Int. Appl., 126 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002006278	A1	20020124	WO 2001-IB1262	20010716
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
IN 193550	A	20040724	IN 2000-DE654	20000717
CA 2415965	AA	20020124	CA 2001-2415965	20010716
AU 2001069370	A5	20020130	AU 2001-69370	20010716
EP 1303511	A1	20030423	EP 2001-947730	20010716
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012826	A	20030624	BR 2001-12826	20010716
JP 2004504321	T2	20040212	JP 2002-512181	20010716
NZ 523700	A	20041126	NZ 2001-523700	20010716
WO 2003008389	A1	20030130	WO 2002-IB167	20020118
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1409464	A1	20040421	EP 2002-787165	20020118
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
WO 2003007870	A2	20030130	WO 2002-IB1609	20020510
WO 2003007870	A3	20030530		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1409465	A2	20040421	EP 2002-727869	20020510
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003000471	A	20031029	ZA 2003-471	20030117
US 2004242591	A1	20041202	US 2004-483905	20040713
US 2004254162	A1	20041216	US 2004-483904	20040713
PRIORITY APPLN. INFO.:			IN 2000-DE654	A 20000717
			WO 2001-IB1262	W 20010716
			WO 2002-IB167	W 20020118
			WO 2002-IB1609	W 20020510

OTHER SOURCE(S) :  
GI

MARPAT 136:134748



AB Oxazolidinones I [T = 5-7-membered heterocyclic ring, aryl; R = CN, acyl, (un)substituted CO<sub>2</sub>H, NH<sub>2</sub>, CONH<sub>2</sub>, alkyl, CH<sub>2</sub>CH:NOH, CH:CH<sub>2</sub>, NO<sub>2</sub>; X = CH, CHS, CHO, N; Y, Z = H, alkyl, cycloalkyl, C0-3 bridging group; U, V = (un)substituted alkyl, H, F, Cl, Br; W = CH<sub>2</sub>, CO, CH<sub>2</sub>NH, NHCH<sub>2</sub>, (un)substituted CH<sub>2</sub>NHCH<sub>2</sub>, S, CH<sub>2</sub>CO, NH; R<sub>1</sub> = acylamino, (un)substituted NH<sub>2</sub>, NHCSR<sub>2</sub>, NHCS<sub>2</sub>R<sub>2</sub>; R<sub>2</sub> = H, (un)substituted alkyl, cycloalkyl, alkoxy; n = 0-3] were prepared. The compds. are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including gram-pos. aerobic bacteria such as multiply-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms such as *Bacterioides* spp. and *Clostridia* spp. species, and acid fast organisms such as *Mycobacterium tuberculosis*, *Mycobacterium avium* and *Mycobacterium* spp. Thus, the furoyl derivative II was prepared from the 4-unsubstituted piperdine fragment and furoyl chloride. II had min. inhibitory concns. against methicillin-resistant *Staph. aureus* 15187 and against *Enterococcus fecalis* 29212 of 2 µg/mL.

IT 392659-92-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of azacycloalkylphenyloxazolidinones as antimicrobials)

RN 392659-92-6 CAPLUS

CN 2-Thiopheneacetamide, N-[(1α,5α,6α)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2001:489375 CAPLUS  
 DOCUMENT NUMBER: 135:92552  
 TITLE: New azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias  
 INVENTOR(S): Bjoersne, Magnus; Ponten, Fritiof; Strandlund, Gert; Svensson, Peder  
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.  
 SOURCE: PCT Int. Appl., 126 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001047893	A1	20010705	WO 2000-SE2604	20001219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2394097	AA	20010705	CA 2000-2394097	20001219
AU 2001025659	A5	20010709	AU 2001-25659	20001219
AU 777069	B2	20040930		
EP 1244631	A1	20021002	EP 2000-989114	20001219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2000016678	A	20021015	BR 2000-16678	20001219
EE 200200305	A	20030616	EE 2002-305	20001219
JP 2003519128	T2	20030617	JP 2001-549365	20001219
NZ 519497	A	20040227	NZ 2000-519497	20001219
RU 2262505	C2	20051020	RU 2002-114821	20001219
US 2002137766	A1	20020926	US 2001-763892	20010228
US 6559162	B2	20030506		
ZA 2002004310	A	20030829	ZA 2002-4310	20020529
NO 2002003038	A	20020822	NO 2002-3038	20020621
PRIORITY APPLN. INFO.:			SE 1999-4765	A 19991223
			WO 2000-SE2604	W 20001219

OTHER SOURCE(S):  
GI

MARPAT 135:92552



I


AB Title compds. I wherein the wavy bond represents optional endo- or exo-stereochem. and wherein R1, R2, R3 and Ra to Rh represent meanings which are exemplified by the example: tert-Bu 8-[[3-(4-cyanoanilino)propyl](methyl)amino]-3-azabicyclo-[3.2.1]octane-3-carboxylate (II) and which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias,. A process for the preparation of compds. of formula I and intermediate compds. which comprises combining [[[azabicyclo[3.2.1]octyl(methyl)amino]propyl]amino]benzonitrile with di-tert-Bu dicarbonate in dichloromethane. E.g., 4-[[3-[3-azabicyclo[3.2.1]oct-8-yl(methyl)amino]propyl]amino]benzonitrile reacts with di-tert-Bu dicarbonate in dichloromethane at 25° to give II in 40% yield.

IT 349448-49-3P 349448-54-0P 349448-57-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation and use in the treatment of cardiac arrhythmias)


RN 349448-49-3 CAPLUS

CN 4-Imidazolidineacetamide, N-[3-[3-[(4-cyanophenyl)amino]propyl]-3-azabicyclo[3.2.1]oct-8-yl]-N-methyl-2,5-dioxo- (9CI) (CA INDEX NAME)




RN 349448-54-0 CAPLUS

CN 4-Imidazolidineacetamide, N-[3-[3-[(4-cyanophenyl)sulfonyl]propyl]-3-azabicyclo[3.2.1]oct-8-yl]-N-methyl-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 349448-57-3 CAPLUS  
 CN 4-Imidazolidineacetamide, N-[3-[2-(4-cyanophenoxy)ethyl]-3-azabicyclo[3.2.1]oct-8-yl]-N-methyl-2,5-dioxo- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1998:394325 CAPLUS  
 DOCUMENT NUMBER: 129:67702  
 TITLE: Preparation of 6-phenylpyridyl-2-amines as NOS inhibitors  
 INVENTOR(S): Lowe, John Adams III  
 PATENT ASSIGNEE(S): Pfizer Inc., USA; Lowe, John Adams III  
 SOURCE: PCT Int. Appl., 61 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9824766	A1	19980611	WO 1997-IB1446	19971117
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2273479	AA	19980611	CA 1997-2273479	19971117
CA 2273479	C	20060207		
AU 9747917	A1	19980629	AU 1997-47917	19971117
EP 946512	A1	19991006	EP 1997-910587	19971117
EP 946512	B1	20031008		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
CN 1239952	A	19991229	CN 1997-180350	19971117
CN 1117077	B	20030806		
BR 9714381	A	20000502	BR 1997-14381	19971117
JP 2000505814	T2	20000516	JP 1998-525397	19971117
JP 3604399	B2	20041222		
NZ 335733	A	20010126	NZ 1997-335733	19971117

AT 251612	E	20031015	AT 1997-910587	19971117
PT 946512	T	20040130	PT 1997-910587	19971117
ES 2206691	T3	20040516	ES 1997-910587	19971117
CZ 293863	B6	20040818	CZ 1999-2017	19971117
TW 491840	B	20020621	TW 1997-86117501	19971122
ZA 9710906	A	19990609	ZA 1997-10906	19971204
AP 848	A	20000609	AP 1997-1156	19971204
W: BW, GM, KE, UG, ZM, ZW				
US 6235750	B1	20010522	US 1999-325480	19990603
NO 9902725	A	19990604	NO 1999-2725	19990604
NO 313517	B1	20021014		
KR 2000057413	A	20000915	KR 1999-704981	19990604
BG 103540	A	20001229	BG 1999-103540	19990630
US 6333186	B1	20011225	US 2000-478479	20000106
US 2002032191	A1	20020314	US 2001-802086	20010308
AU 2001072050	A5	20011115	AU 2001-72050	20010913
AU 766080	B2	20031009		
US 2002103227	A1	20020801	US 2001-965564	20010927
US 2002106642	A1	20020808	US 2001-965594	20010927
US 6800456	B2	20041005		
US 2004142924	A1	20040722	US 2003-678369	20031003
JP 2005170924	A2	20050630	JP 2004-186311	20040624
PRIORITY APPLN. INFO.:				
			US 1996-32793P	P 19961206
			AU 1997-47917	A3 19971117
			JP 1998-525397	A3 19971117
			WO 1997-IB1446	W 19971117
			US 1999-325480	A1 19990603
			US 2000-478479	A3 20000106
			US 2001-802086	B3 20010308
			US 2001-965594	A1 20010927


OTHER SOURCE(S): MARPAT 129:67702  
GI




I



II



III



IV

AB The title compds. [I; G = II, III (n = 0, 1; Y = NR3R4, C1-6 alkyl, (un)substituted aralkyl; X = N when Y = (un)substituted C1-6 alkyl, aralkyl, and X = CH when Y = NR3R4; q = 0-2; m = 0-2; R3, R4 = C1-6 alkyl, tetrahydronaphthalene and aralkyl; NR3R4 = piperazino, pyrrolidino, etc.)]



and their salts, which exhibit activity as nitric oxide synthase (NOS) inhibitors and as such useful in the treatment and prevention of central nervous system and other disorders, were prepared. Thus, e.g., the detailed 7-step synthesis of the title compound IV is described. Of 100 compds. I that were tested, all exhibited an IC50 of < 10 µM for inhibition of either inducible or neuronal NOS.


IT 208837-50-7P 208837-52-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 6-phenylpyridyl-2-amines as NOS inhibitors)


RN 208837-50-7 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-[[[4'-(6-(2,5-dimethyl-1H-pyrrol-1-yl)-2-pyridinyl)[1,1'-biphenyl]-4-yl]acetyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 208837-52-9 CAPLUS

CN [1,1'-Biphenyl]-4-acetamide, 4'-(6-amino-2-pyridinyl)-N-3-azabicyclo[3.1.0]hex-6-yl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1997:679059 CAPLUS

DOCUMENT NUMBER: 127:346302

TITLE: 6-phenylpyridyl-2-amine derivatives as nitric oxide synthase inhibitors

INVENTOR(S): Lowe, John Adams, III; Whittle, Peter John

PATENT ASSIGNEE(S): Pfizer Inc., USA; Lowe, John Adams, III; Whittle, Peter John

SOURCE: PCT Int. Appl., 118 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9736871	A1	19971009	WO 1997-IB132	19970217
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU				

RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,  
 IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML,  
 MR, NE, SN, TD, TG

CA 2250372	C	19971009	CA 1997-2250372	19970217
CA 2250372	AA	19971009		
AU 9715548	A1	19971022	AU 1997-15548	19970217
AU 729129	B2	20010125		
EP 891332	A1	19990120	EP 1997-901748	19970217
EP 891332	B1	20040317		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LV, FI, RO				
CN 1215391	A	19990428	CN 1997-193526	19970217
BR 9708386	A	19990803	BR 1997-8386	19970217
JP 11510513	T2	19990914	JP 1997-535075	19970217
JP 3455229	B2	20031014		
NZ 326874	A	20000128	NZ 1997-326874	19970217
IL 125811	A1	20030112	IL 1997-125811	19970217
CZ 291647	B6	20030416	CZ 1998-2614	19970217
AT 261942	E	20040415	AT 1997-901748	19970217
PT 891332	T	20040730	PT 1997-901748	19970217
ES 2214604	T3	20040916	ES 1997-901748	19970217
EP 1471055	A1	20041027	EP 2004-3268	19970217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LV, FI, RO				
CN 1546470	A	20041117	CN 2004-10005825	19970217
NZ 500927	A	20041126	NZ 1997-500927	19970217
TW 438793	B	20010607	TW 1997-86101888	19970218
US 6235747	B1	20010522	US 1997-816235	19970313
HR 970174	A1	20001231	HR 1997-970174	19970326
HR 970174	B1	20020630		
ZA 9702689	A	19980928	ZA 1997-2689	19970327
NO 9804516	A	19980928	NO 1998-4516	19980928
NO 312460	B1	20020513		
KR 2000005127	A	20000125	KR 1998-707773	19980929
BG 64310	B1	20040930	BG 1998-102872	19981027
HK 1018780	A1	20050304	HK 1999-103798	19990902
US 2001034348	A1	20011025	US 2001-826132	20010404
US 6465491	B2	20021015		
PRIORITY APPLN. INFO.:			US 1996-14343P	P 19960329
			EP 1997-901748	A3 19970217
			WO 1997-IB132	W 19970217
			US 1997-816235	A3 19970313
OTHER SOURCE(S):		MARPAT 127:346302		
GI				




AB Title compds. I [NR1R2 = amino; R3, R4 = H, alkyl, aralkyl; R5, R6 = Me, OMe, OH, H; R7 = alkyl; m, n = 1-2] were prepared and exhibit activity as nitric oxide synthase (NOS) inhibitors for use in the treatment and prevention of central nervous system disorders (no data). Thus, the amine II was prepared from 2,6-dibromopyridine and 4-H2NC6H4CH2CH2OH via 2-(2,5-dimethylpyrrol-1-yl)-6-[4-(2-chloroethyl)phenyl]pyridine.

IT 198210-03-6P  
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of aminoethylphenylpyridylamines as nitric oxide synthase inhibitors)

RN 198210-03-6 CAPLUS

CN Benzeneacetamide, N-[3-[2-[4-(6-amino-2-pyridinyl)phenyl]ethyl]-3-azabicyclo[3.1.0]hex-6-yl]-4-fluoro- (9CI) (CA INDEX NAME)



L4 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1993:517227 CAPLUS

DOCUMENT NUMBER: 119:117227

TITLE: Preparation of azabicycloalkylquinolones and -naphthyridinones as antibacterials

INVENTOR(S): Brighty, Katherine E.

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: U.S., 42 pp. Cont.-in-part of U.S. Ser. No. 551,212, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5164402	A	19921117	US 1991-650835	19910204


US 5229396	A	19930720	US 1992-919477	19920724
US 5266569	A	19931130	US 1993-12202	19930202
US 5391763	A	19950221	US 1993-88999	19930826

PRIORITY APPLN. INFO.:

		US 1990-551212	B2 19900711
		US 1991-650835	A3 19910204
		US 1992-919477	A3 19920724
		US 1993-12202	A3 19930202

OTHER SOURCE(S):                    MARPAT 119:117227

GI




AB Title compds. [I; R<sub>1</sub> = H, alkyl, pharmaceutically acceptable cation; Y = Et, Me<sub>3</sub>C, vinyl cyclopropyl, FCH<sub>2</sub>CH<sub>2</sub>, 4-FC<sub>6</sub>H<sub>4</sub>, 2,4-F<sub>2</sub>C<sub>6</sub>H<sub>3</sub>; W = F, Cl, Br, alkyl, alkoxy, (methyl)amino; A = CH, CCl, C(OMe), CMe, CCN, N; AY = atoms to form a (0-or double bond-containing) (substituted) 5-6 membered ring; R<sub>2</sub> = Q<sub>1</sub>, Q<sub>2</sub>; R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, R<sub>9</sub> = H, Me, CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>NHMe, CH<sub>2</sub>NH<sub>2</sub>Et; R<sub>5</sub>, R<sub>6</sub>, R<sub>1</sub>, R<sub>9</sub> may also = NH<sub>2</sub>, NHMe, NH<sub>2</sub>Et; ≤3 of R<sub>3</sub>, R<sub>4</sub>, R<sub>6</sub>, R<sub>7</sub>, R<sub>9</sub>, R<sub>10</sub>, R<sub>25</sub> ≠ H; if 3 of these ≠ H, ≥1 of them = Me], were prepared as antibacterials (no data). Thus, 3-azabicyclo[3.1.0]hexane hydrochloride was heated with 1-cyclopropyl-6,7-difluoro-1,4-dihydro-4-oxoquinolinecarboxylic acid and Et<sub>3</sub>N in MgSO to give title compound II.

IT 146961-74-2P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of, as antibacterial)

RN 146961-74-2 CAPLUS

CN L-Phenylalaninamide, glycyl-N-[3-[6-carboxy-8-(2,4-difluorophenyl)-3-fluoro-5,8-dihydro-5-oxo-1,8-naphthyridin-2-yl]-3-azabicyclo[3.1.0]hex-6-yl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


IT 146655-53-0P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as intermediate for antibacterial)

RN 146655-53-0 CAPLUS

CN L-Phenylalaninamide, N-[(phenylmethoxy)carbonyl]glycyl-N-[3-[6-carboxy-8-(2,4-difluorophenyl)-3-fluoro-5,8-dihydro-5-oxo-1,8-naphthyridin-2-yl]-3-azabicyclo[3.1.0]hex-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d his

(FILE 'HOME' ENTERED AT 09:57:52 ON 15 SEP 2006)

FILE 'REGISTRY' ENTERED AT 09:58:09 ON 15 SEP 2006

L1 STRUCTURE UPLOADED

L2 10 S L1

L3 347 S L1 FULL

FILE 'CAPLUS' ENTERED AT 09:58:45 ON 15 SEP 2006

L4 18 S L3 FULL

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

95.20

262.35

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-13.50

-13.50

STN INTERNATIONAL LOGOFF AT 10:02:56 ON 15 SEP 2006